[go: up one dir, main page]

WO2010016940A2 - Analogues of glucose-dependent insulinotropic polypeptide - Google Patents

Analogues of glucose-dependent insulinotropic polypeptide Download PDF

Info

Publication number
WO2010016940A2
WO2010016940A2 PCT/US2009/004552 US2009004552W WO2010016940A2 WO 2010016940 A2 WO2010016940 A2 WO 2010016940A2 US 2009004552 W US2009004552 W US 2009004552W WO 2010016940 A2 WO2010016940 A2 WO 2010016940A2
Authority
WO
WIPO (PCT)
Prior art keywords
aib
succinimide
seq
hgip
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/004552
Other languages
French (fr)
Other versions
WO2010016940A3 (en
Inventor
Zheng Xin Dong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Ipsen Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2011001031A priority Critical patent/MX2011001031A/en
Priority to KR1020137020218A priority patent/KR101417873B1/en
Priority to CN200980139514.2A priority patent/CN102171244B/en
Priority to EA201170304A priority patent/EA020019B1/en
Priority to EP20090805293 priority patent/EP2328922A4/en
Priority to AU2009280017A priority patent/AU2009280017B2/en
Priority to US13/057,760 priority patent/US9074014B2/en
Priority to BRPI0916890A priority patent/BRPI0916890A2/en
Application filed by Ipsen Pharma SAS filed Critical Ipsen Pharma SAS
Priority to JP2011522070A priority patent/JP2011530508A/en
Priority to CA2732949A priority patent/CA2732949C/en
Publication of WO2010016940A2 publication Critical patent/WO2010016940A2/en
Publication of WO2010016940A3 publication Critical patent/WO2010016940A3/en
Anticipated expiration legal-status Critical
Priority to US14/717,186 priority patent/US20150252092A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to the area of novel analogues of glucose-dependent insulinotropic polypeptide, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.
  • GIP Glucose-dependent insulinotropic polypeptide
  • SEQ ID NO: 1 Glucose-dependent insulinotropic polypeptide
  • GIP inhibits the secretion of gastric acid, and it has been shown to be a potent stimulant for the secretion of insulin from pancreatic beta cells after oral glucose ingestion (the "incretin effect") (Creutzfeldt, W., et al, 1979, Diabetologia, 16:75-85).
  • GIP and GLP-I GIP and glucagon-like peptide 1
  • GIP GIP-associated diabetes
  • a disease selected from the group consisting of type 1 diabetes, type 2 diabetes (Visboll, T., 2004, Dan. Med. Bull, 51 :364-70), insulin resistance (WO 2005/082928), obesity (Green, B. D., et al, 2004, Current Pharmaceutical Design, 10:3651-3662), metabolic disorder (Gault, V. A., et al, 2003, Biochem. Biophys. Res.
  • GIP pancreatic beta cells
  • GIP In addition to effects on the pancreas to enhance insulin secretion, GIP also has effects on insulin target tissues directly to lower plasma glucose: enhancement of glucose uptake in adipose (Eckel, et al, 1979, Diabetes, 28: 1141-1142) and muscle (O'Harte, et al, 1998, J. Endocrinol., 156:237-243), and inhibition of hepatic glucose production (Elahi, D., et al, 1986, Can. J. Physiol. Pharmacol., 65: Al 8).
  • a GIP receptor antagonist in accordance with the present invention inhibits, blocks or reduces glucose absorption from the intestine of an animal.
  • compositions containing GIP antagonists may be used in patients with non- insulin dependent diabetes mellitus to improve tolerance to oral glucose in mammals, such as humans, to prevent, inhibit or reduce obesity by inhibiting, blocking or reducing glucose absorption from the intestine of the mammal.
  • PCT publication WO 00/58360 discloses peptidyl analogues of GIP which stimulate the release of insulin.
  • this application discloses specific peptidyl analogues comprising at least 15 amino acid residues from the N-terminal end of GIP(I -42), e.g., an analogue of GIP containing exactly one amino acid substitution or modification at positions 1, 2 and 3, such as [Pro 3 ]GIP(l-42).
  • PCT publication WO 98/24464 discloses an antagonist of GIP consisting essentially of a 24- amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP, a method of treating non-insulin dependent diabetes mellitus and a method of improving glucose tolerance in a non-insulin dependent diabetes mellitus patient.
  • PCT publication WO 03/082898 discloses C-terminal truncated fragments and N-terminal modified analogues of GEP, as well as various GEP analogues with a reduced peptide bond or alterations of the amino acids close to the DPPEV-specific cleavage site.
  • This application further discloses analogues with different linkers between potential receptor binding sites of GIP.
  • the compounds of this application are alleged to be useful in treating GlP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.
  • the invention relates to peptide variants of GIP of the following formula (I):
  • a 1 is Tyr, 4Hppa, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 2 is Ala, Abu, D-Abu, Ace, Aib, ⁇ -Ala, D-AIa, Gaba, GIy, Ser, D-Ser, Thr, D-Thr, VaI, or D-VaI;
  • a 3 is GIu, Aib, Asp, NMe-Asp, Dhp, Dmt, GIu, NMe-GIu, 3Hyp, 4Hyp, 4Ktp, Pro, hPro, Thz, or Tic;
  • a 4 is GIy, Ace, Aib, or ⁇ -Ala;
  • a 5 is Thr, Ace, Aib, or Ser;
  • a 6 is Phe, Ace, Aib, Aic, Cha, INaI, 2NaI, 2-Pal, 3-Pal, 4-Pal, (X 4 ,X 5 ,X 6 ,X 7 ,X 8 )Phe, or Trp;
  • a 7 is lie, Abu, Ace, Aib, Ala, Cha, Leu, NIe, Phe, Tie, or VaI;
  • a 8 is Ser, Aib, or Thr;
  • a 9 is Asp, Aib, or GIu;
  • a 10 is Tyr, Ace, Cha, INaI, 2NaI, 2-Pal, 3-Pal, 4-Pal, Phe, or (X 4 ,X 5 ,X 6 ,X 7 ,X 8 )Phe;
  • a 11 is Ser, Ace, Aib, NIe, or Thr;
  • a 12 is He, Abu, Ace, Aib, Ala, Cha, Leu, NIe, Phe, Tie, or VaI;
  • a 13 is Ala, Ace, Aib, ⁇ -Ala, D-AIa, GIy, or Ser;
  • a 14 is Met, Abu, Ace, Aib, Ala, Cha, He, Leu, NIe, Phe, Tie, or VaI;
  • a 15 is Asp, Aib, or GIu;
  • a 16 is Lys, Amp, Ape, Arg, hArg, Orn, HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O), Cys(succinimide-N- alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH 2 ) x -C(O)-NH-
  • a 17 is Ee, Abu, Ace, Aib, Ala, Cha, Leu, NIe, Phe, Tie, or VaI;
  • a 18 is His, Amp, Arg, 2-Pal, 3-Pal, 4-Pal, Phe, or Tyr;
  • a 19 is GIn, Aib, or Asn;
  • a 20 is GIn, Aib, or Asn
  • a 21 is Asp, Aib, or GIu;
  • a 22 is Phe, Ace, Aib, Aic, Cha, INaI, 2NaI, 2-Pal, 3-Pal, 4-Pal, (X 4 ,X 5 ,X 6 ,X 7 ,X 8 )Phe, or Trp;
  • a 23 is VaI, Abu, Ace, Aib, Ala, Cha, Ee, Leu, NIe, or Tie;
  • a 24 is Asn, Aib, or GIn;
  • a 25 is Trp, Ace, Aib, INaI, 2NaI, 2-Pal, 3-Pal, 4-Pal, Phe, or (X 4 ,X 5 ,X 6 ,X 7 ,X 8 )Phe;
  • a 26 is Leu, Ace, Aib, Cha, Ee, NIe, Phe, (X 4 ,X 5 ,X 6 ,X 7 ,X 8 )Phe, or Tie;
  • a 27 is Leu, Ace, Aib, Cha, Be, NIe, Phe, (X 4 ,X 5 ,X 6 ,X 7 ,X 8 )Phe, or Tie,;
  • a 28 is Ala, Ace, or Aib;
  • a 29 is GIn, Aib, Asn, or deleted;
  • a 30 is Lys, Amp, Ape, Arg, hArg, Orn, HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O), Cys(succinimide-N- alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH 2 ) x -C(O)-NH- (CH 2 ) y -CH 3 ), hCys(succinimide-N-(CH 2 ) x -C(O)-NH-(CH 2 ) y -CH 3 ), Pen(succinimide-N-(CH 2 ) x -C(O)- NH-(CH 2 ) y -CH 3 ), Cys(succinimide-N-(CH 2 ) s -NH-C(O)-(CH 2 ),-CH
  • a 31 is GIy, Ace, Aib, ⁇ -Ala, HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH 2 ) x -C(O)-NH-(CH 2 ) y - CH 3 ), hCys(succinimide-N-(CH 2 ) x -C(O)-NH-(CH 2 ) y -CH 3 ), Pen(succinimide-N-(CH 2 ) x -C(O)-NH- (CH 2 ) y -CH 3 ), Cys(succinimide-N-(CH 2 ) s -NH-C(O)-(CH 2 ) t -CH 3
  • a 32 is Lys, Amp, Ape, Arg, hArg, Orn, HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O), Cys(succinimide-N- alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH 2 ) x -C(O)-NH- (CH 2 ) y -CH 3 ), hCys(succinimide-N-(CH 2 ) x -C(O)-NH-(CH 2 ) y -CH 3 ), Pen(succinimide-N-(CH 2 ) x -C(O)- NH-(CH 2 ) y -CH 3 ), Cys(succinimide-N-(CH 2 ) s -NH-C(O)-(CH 2 ) r
  • a 33 is Lys, Amp, Ape, Arg, hArg, Om, HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O), Cys(succinimide-N- alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH 2 ) x -C(O)-NH- (CH 2 ) y -CH 3 ), hCys(succinimide-N-(CH 2 ) x -C(O)-NH-(CH 2 ) y -CH 3 ), Pen(succinimide-N-(CH 2 ) x -C(O)- NH-(CH 2 ) y -CH 3 ), Cys(succinimide-N-(CH 2 ) s -NH-C(O)-(CH 2 ) r CH
  • a 34 is Asn, Aib, GIn, Ser, HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH 2 ) x -C(O)-NH-(CH 2 ) y - CH 3 ), hCys(succinimide-N-(CH 2 ) x -C(O)-NH-(CH 2 ) y -CH3), Pen(succinimide-N-(CH 2 ) )C -C(O)-NH- (CH 2 ) y -CH 3 ), Cys(succinimide-N-(CH 2 ) s -NH-C(O)-(CH 2 ) t -CH 3 ), h
  • a 35 is Asp, Aib, GIu, HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH 2 ) x -C(O)-NH-(CH 2 ) y - CH 3 ), hCys(succinimide-N-(CH 2 ) x -C(O)-NH-(CH 2 ) y -CH 3 ), Pen(succinimide-N-(CH 2 ) x -C(O)-NH- (CH 2 ) y -CH 3 ), Cys(succinimide-N-(CH 2 ) s -NH-C(O)-(CH 2 ) t -CH 3 ), hC
  • a 36 is Tip, Ace, Aib, INaI, 2NaI, 2-Pal, 3-Pal, 4-Pal, Phe, (X 4 ,X 5 ,X 6 ,X 7 ,X 8 )Phe, HN- CH((CH 2 ) n -N(R 4 R 5 ))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide- N-alkyl), Cys(succinimide-N-(CH 2 ) x -C(O)-NH-(CH 2 ) y -CH 3 ), hCys(succinimide-N-(CH 2 ) x -C(O)-NH- (CH 2 ) y -CH 3 ), Pen(succinimide-N-(CH 2 ) x -C(O)-NH-(CH 2 ) y -CH
  • a 39 is Asn, Aib, GIn, HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH 2 ) x -C(O)-NH-(CH 2 ) y - CH 3 ), hCys(succinimide-N-(CH 2 ) x -C(O)-NH-(CH 2 ) y -CH 3 ), Pen(succinimide-N-(CH 2 ) x -C(O)-NH- (CH 2 ) y -CH 3 ), Cys(succinimide-N-(CH 2 ) s -NH-C(O)-(CH 2 ) t -CH 3 ), hCy
  • a 40 is He, Ace, Aib, Ser, Thr, HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH 2 ) x -C(O)-NH-(CH 2 ) y - CH 3 ), hCys(succinimide-N-(CH 2 ) x -C(O)-NH-(CH 2 ) y -CH 3 ), Pen(succinimide-N-(CH 2 ) x -C(O)-NH- (CH 2 ) y -CH 3 ), Cys(succinimide-N-(CH 2 ) s -NH-C(O)-(CH 2 ) r CH 3 ), hC
  • a 41 is Thr, Ace, Aib, Asn, GIn, HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH 2 ) x -C(O)-NH-(CH 2 ) y - CH 3 ), hCys(succinimide-N-(CH 2 ) ⁇ -C(O)-NH-(CH 2 ) y -CH 3 ), Pen(succinimide-N-(CH 2 ) x -C(O)-NH- (CH 2 ) y -CH 3 ), Cys(succinimide-N-(CH 2 ) s -N ⁇ -C(O)-(CH 2 ) r CH3), hC
  • a 42 is GIn, Ace, Aib, Asn, HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH 2 ) x -C(O)-NH-(CH 2 ) y - CH 3 ), hCys(succinimide-N-(CH 2 ) x -C(O)-NH-(CH 2 ) y -CH 3 ) ) Pen(succinimide-N-(CH 2 ) x -C(O)-NH- (CH 2 ) y -CH 3 ) ) Cys(succinimide-N-(CH 2 ) s -NH-C(O)-(CH 2 ) t -CH 3
  • a 43 is Ace, Aib, Ala, Asp, GIn, His, Phe, Thr, Tip, HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide- N-(CH 2 ) x -C(O)-NH-(CH 2 ) y -CH 3 ), hCys(succinimide-N-(CH 2 ) x -C(O)-NH-(CH 2 ) y -CH 3 ), Pen(succinimide-N-(CH 2 ) x -C(O)-NH-(CH 2 ) y -CH 3 ), Cys(succinimide-N-(CH 2 ) s -NH-C(O)-(
  • X 4 , X 5 , X 6 , X 7 and X 8 each is, independently for each occurrence, H, F, Cl, Br, I, (Ci.io)alkyl, substituted (C M0 )alkyl, aryl, substituted aryl, OH, NH 2 , NO 2 , or CN; provided that when A 1 is 4Hppa, then R 2 and R 3 are deleted; further provided that only one amino acid at positions 1, 2 and 3 of the compound is substituted or modified; and further provided that a compound of formula (I) is not (D-Ala 2 )hGIP(l-42), (Pro 3 )hGIP(l-42) (SEQ ID NO:120), (Aib 3 )hGIP(l-42) (SEQ ID NO: 121), (Ser 2 )hGIP(l-42) (SEQ ED NO:122), (Abu 2 )hGIP(l-42) (SEQ ID NO: 123), (D-Abu
  • a subset (A) of the compounds covered by the above formula (I) are those in which:
  • a 1 is Tyr, 4HpPa, or Orn(N-C(O)-(CH 2 ) 12 -CH 3 );
  • a 2 is Ala, A5c, A6c, Aib, D-AIa, GIy, or Ser;
  • a 3 is GIu, Dhp, 3Hyp, 4Hyp, Pro, hPro, or Tic;
  • a 4 is GIy or Aib
  • a 5 is Thr, A5c, or Aib;
  • a 6 is Phe or A6c
  • a 7 is He, A5c, A6c, or Aib
  • a 8 is Ser or Aib
  • a 9 is Asp or Aib
  • a 10 is Tyr
  • a 11 is Ser, A5c, A6c, Aib, or NIe;
  • a 12 is lie, A5c, or Aib;
  • a 13 is Ala or Aib
  • a 14 is Met, A5c, A6c, or NIe;
  • a 15 is Asp
  • a 18 is His
  • a 19 is GIn
  • a 20 is GIn
  • a 23 is VaI
  • a 24 is Asn
  • a 25 is Trp
  • a 26 is Leu or A6c
  • a 27 is Leu or A6c
  • a 28 is Ala or Aib
  • a 29 is GIn
  • a 30 is Lys
  • a 31 is GIy, Aib, Cys(Psu), His, or deleted;
  • a 32 is Lys, Cys(Psu), or deleted;
  • a 33 is Lys, Cys(Psu), or deleted
  • a 34 is Asn, Cys(Psu), or deleted;
  • a 35 is Asp, Cys(Psu), or deleted;
  • a 36 is Trp, Cys(Psu), or deleted;
  • a 37 is Lys, Cys(Psu), or deleted;
  • a 38 is His, Cys(Psu), or deleted;
  • a 39 is Asn, Cys(Psu), or deleted;
  • a 40 IS Ee, A5c, A6c, Cys(Psu), or deleted;
  • a 41 is Thr, A5c, A6c, Aib, Cys(Psu), or deleted;
  • a 42 is GIn or deleted;
  • a 43 is Cys(Psu), GIn, His, or deleted, and provided that the compound contains at least one additional amino acid substitution or modification at positions 4-43.
  • a subset of the compounds of the preceding subset (A) are those in which A 2 is D-AIa.
  • Another subset of the compounds of the preceding subset (A) are those in which A 31 to A 43 are deleted.
  • Another subset of the compounds of the preceding subset (A) are those in which A 2 is Ala,
  • A5c, A6c, or GIy is GIu, Dhp, 3Hyp, 4Hyp, hPro, or Tic.
  • Another aspect of the present invention encompasses compounds consisting essentially of a sequence of the first 30 consecutive amino acid residues from the N-termmal end of the native hGIP ammo acid sequence, wherein the sequence comprises A5c, A6c, Aib, D-AIa, GIy or Ser substitution at position 2, and at least one additional ammo acid substitution or modification at positions 3-30.
  • a subset of the compounds of the immediately preceding aspect of the present invention are those in which A 2 is Aib; A 3 is Pro; and at least one of A 7 , A 11 , A 13 and A 14 is not the amino acid residue of the corresponding position in the native GIP.
  • Yet another aspect of the present invention encompasses GIP analogues comprising A5c, A6c, Aib, D-AIa, GIy or Ser substitution at position 2, and at least one additional amino acid substitution or modification at positions 1 and 3-42.
  • a subset of the compounds of the immediately preceding aspect of the present invention are those in which A 2 is Aib.
  • Preferred compounds of formula (I) are: Example 1: (Aib 2 ' ⁇ )hGIP(l-42)-0H (SEQ ID NO:4);
  • Example 5 (Aib 2 , A5c 5 )hGIP(l-42)-OH (SEQ ID NO: 8);
  • Example 6 (Aib 2 , A5c 7 )hGIP(l -42)-OH (SEQ ID NO:9);
  • Example 7 (Aib 2 , A5c 12 )hGIP(l-42)-OH (SEQ ID NO: 10);
  • Example 8 (Aib 2 ' 12 )hGIP(l-42)-OH (SEQ ID NO: 11);
  • Example 11 (Aib 2 , A5c 5 )hGIP(l -3O)-NH 2 (SEQ ID NO: 14);
  • Example 12 (Aib 2 , A5c 7 )hGD?(l -3O)-NH 2 (SEQ ID NO: 15);
  • Example 13 (Aib 2 , A5c 12 )hGIP(l -3O)-NH 2 (SEQ ID NO: 16);
  • Example 14 (Aib 2 ' 4 )hGIP( 1-3 O)-NH 2 (SEQ ID NO: 17);
  • Example 15 (Aib 2 ' 5 )hGIP(l -3O)-NH 2 (SEQ ID NO: 18);
  • Example 16 (Aib 2 ' 7 )hGIP(l -3O)-NH 2 (SEQ ID NO: 19);
  • Example 17 (Aib 2 ' 8 )hGIP(l -3O)-NH 2 (SEQ ID NO:20);
  • Example 18 (Aib 2 ' 9 )hGIP(l -3O)-NH 2 (SEQ ID NO:21);
  • Example 20 (Aib 2 ' 12 )hGIP(l -3O)-NH 2 (SEQ ID NO:23);
  • Example 21 (Aib 2 ' 13 , A6c 7 , Nle 14 )hGD?(l-42)-OH (SEQ ID NO:24);
  • Example 22 (Aib 2 ' 3I , A6c 7 )hGIP(l-42)-OH (SEQ ID NO:25);
  • Example 23 (Aib 2 ' 41 , A6c 7 )hGIP(l-42)-OH (SEQ ID NO:26);
  • Example 24 (Aib 2 ' 31 , A6c 7 , Nle 14 )hGC?(l-42)-OH (SEQ ID NO:27);
  • Example 25 (Aib 2 ' 41 , A6c 7 , Nle M )hGIP(l-42)-OH (SEQ ID NO:28);
  • Example 26 (Aib 2 , A6c 7 ' 26 , Nle 14 )hGIP(l-42)-OH (SEQ ID NO:29);
  • Example 27 (Aib 2 , A6c 7 ' 27 , Nle 14 )hGIP(l-42)-OH (SEQ ID NO:30);
  • Example 28 (Aib 2 , A6c 7 ' 40 , Nle 14 )hGIP(l-42)-OH (SEQ ID NO:31);
  • Example 29 (Aib 2 , A6c 7 ' 41 , Nle' 4 )hGIP(l-42)-OH (SEQ ID NO:32);
  • Example 30 (Aib 2 ' 28 , A6c 7 , Nle 14 )hGIP(l-42)-OH (SEQ ID NO:33);
  • Example 31 (Aib 2 , A6c 7 , Nle 14 )hGIP(l-30)-NH 2 (SEQ ID NO:34);
  • Example 32 (Aib 2 , A5c 7 , Nle 14 )hGIP(l -3O)-NH 2 (SEQ ID NO:35);
  • Example 33 (Aib 2 ' ", Nle 14 )hGIP(l -3O)-NH 2 (SEQ ID NO:36);
  • Example 34 (A5c 2 ' 7 , Nle 14 )hGIP(l -3O)-NH 2 (SEQ ID NO:37);
  • Example 35 (Aib 2 , A5c 7 ' 14 )hGIP(l -3O)-NH 2 (SEQ ID NO:38);
  • Example 36 (A6c 2 ' 7 , Nle 14 )hGIP(l -3O)-NH 2 (SEQ ID NO:39);
  • Example 37 (Aib 2 , A6c 7 ' ", Nle l4 )hGIP(l-42)-OH (SEQ ID NO:40);
  • Example 38 (Aib 2 ' ", A6c 14 )hGD?(l-30)-NH 2 (SEQ ID NO:41);
  • Example 39 (Aib 2 , A6c 7 ' 14 )hGIP(l -3O)-NH 2 (SEQ ID NO:42);
  • Example 40 (A5c 2 , Nle l4 )hGIP(l-42)-OH (SEQ ID NO:43);
  • Example 41 (Aib 2 ' ", A6c 14 )hGIP(l-42)-OH (SEQ ID NO:44);
  • Example 42 (Aib 2 , A6c 14 )hGIP(l-42)-OH (SEQ ID NO:45);
  • Example 43 (Aib 2 , A6c 7 )hGIP(l -42)-OH (SEQ ID NO:46);
  • Example 44 (Aib 2 , A5c 7 , A6c M )hGIP(l -42)-OH (SEQ ID NO:47);
  • Example 45 (Aib 2 ' ", Nle 14 )hGIP(l-42)-OH (SEQ ID NO:48);
  • Example 46 (Aib 2 , A5c")hGIP(l-30)-NH 2 (SEQ ID NO:49);
  • Example 47 (Aib 2 ' 13 )hGIP(l -3O)-NH 2 (SEQ ED NO:50);
  • Example 48 (Aib 2 , A5c", A6c 14 )hGIP(l -3O)-NH 2 (SEQ ID NO:51);
  • Example 49 (Aib 2 ' 13 , Nle 14 )hGIP(l-30)-NH 2 (SEQ ID NO:52);
  • Example 50 (Aib 2 , A5c ⁇ , NIe 14 )hGIP( 1-3 O)-NH 2 (SEQ ID NO:53);
  • Example 51 (Aib 2 , A6c 7 ' 14 )hGIP(l-42)-OH (SEQ ID NO:54);
  • Example 52 (Aib 2 , A6c 7 )hGIP(l -3O)-NH 2 (SEQ ID NO:55);
  • Example 53 (Aib 2 , A5c")hGIP(l-42)-OH (SEQ ID NO:56);
  • Example 54 (Aib 2 , A5c", Nle 14 )hGIP(l-42)-OH (SEQ ID NO:57);
  • Example 55 (Aib 2 , A6c 7 , Nle 14 )hGIP(l-42)-OH (SEQ ID NO:58);
  • Example 56 (A5c 2 ' ⁇ A6c 14 )hGIP(l-42)-OH (SEQ ID NO:59);
  • Example 57 (Aib 2> 13 , Nle 14 )hGIP(l-42)-OH (SEQ ID NO:60);
  • Example 58 (Aib 2 , A5c 7 , Nle 14 )hGIP(l-42)-OH (SEQ ID NO:61);
  • Example 59 (Aib 2 , A5c 7> 14 )hGIP(l-42)-OH (SEQ ID NO:62);
  • Example 60 (Aib 2 ' ' 3 )hGIP( 1 -42)-OH (SEQ ID NO : 63);
  • Example 61 (Aib 2 , A5c", A6c 14 )hGIP(l-42)-OH (SEQ ID NO:64);
  • Example 62 (Pro 3 , Aib 13 , Nle 14 )hGIP(l-42)-OH (SEQ ID NO:65);
  • Example 63 (hPro 3 , Aib 13 , Nle 14 )hGIP(l-42)-OH (SEQ ID NO:66);
  • Example 64 (Dhp 3 , Aib 13 , Nle 14 )hGIP(l-42)-OH (SEQ ID NO:67);
  • Example 65 (hPro 3 , Aib 13 )hGIP(l-42)-OH (SEQ ID NO:68);
  • Example 66 (Tic 3 , Aib 13 )hGIP(l-42)-OH (SEQ ID NO:69);
  • Example 67 (4Hyp 3 , Aib 13 )hGIP(l-42)-OH (SEQ ID NO:70);
  • Example 68 (4Hyp 3 , Aib 13 , Nle 14 )hGIP(l-42)-OH (SEQ ID NO:71);
  • Example 69 (Tic 3 , Aib 13 , Nle 14 )hGIP(l-42)-OH (SEQ ID NO:72);
  • Example 70 (3Hyp 3 , Aib 13 , Nle 14 )hGIP(l-42)-OH (SEQ ID NO:73);
  • Example 71 (Tic 3 , A6c' 4 )hGIP(l-42)-OH (SEQ ID NO:74);
  • Example 72 (hPro 3 , A6c 14 )hGIP(l-42)-OH (SEQ ID NO:75);
  • Example 73 [Aib 2 , A6c 7 , Cys(Psu) 41 ]hGIP(l-42)-OH (SEQ ID NO:76);
  • Example 74 (hPro 3 , A5c")hGIP(l-42)-OH (SEQ ID NO:77);
  • Example 75 (Pro 3 , Aib 13 )hGIP(l-42)-OH (SEQ ID NO:78);
  • Example 76 (Pro 3 , A5c 7 ' 14 )hGIP(l-42)-OH (SEQ ID NO:79);
  • Example 77 (Pro 3 , A5c")hGIP(l-42)-OH (SEQ ID NO:80);
  • Example 78 [Aib 2 , A6c 7 , Cys(Psu) 40 ]hGIP(l-42)-OH (SEQ ID NO:81);
  • Example 79 [Aib 2 , A6c 7 , Cys(Psu) 39 ]hGIP(l-42)-OH (SEQ ID NO:82);
  • Example 80 [Aib 2 , A6c 7 , Cys(Psu) 38 ]hGIP(l-42)-OH (SEQ ID NO:83);
  • Example 81 [Aib 2 , A6c 7 , Cys(Psu) 36 ]hGIP(l-42)-OH (SEQ ED NO: 84);
  • Example 82 (Tic 3 , A5c")hGIP(l-42)-OH (SEQ ID NO:85);
  • Example 83 (hPro 3 , A5c u , A6c 14 )hGIP(l-42)-OH (SEQ ED NO:86);
  • Example 84 (4Hyp 3 , A6c 14 )hGEP(l-42)-OH (SEQ ED NO:87);
  • Example 85 [Aib 2 , A6c 7 , Cys(Psu) 35 ]hGEP(l-42)-OH (SEQ ED NO:88);
  • Example 86 [Aib 2 , A6c 7 , Cys(Psu) 34 ]hGEP(l-42)-OH (SEQ ED NO: 89);
  • Example 88 (4Hyp 3 , A5c u , A6c 14 )hGEP(l-42)-OH (SEQ ED NO:91);
  • Example 89 (Tic 3 , A5c ⁇ , A6c 14 )hGEP(l-42)-OH (SEQ ED NO:92);
  • Example 90 [Aib 2 , A6c 7 , Cys(Psu) 31 ]hGEP(l-42)-OH (SEQ ED NO:93);
  • Example 91 (Pro 3 , A6c 14 )hGEP(l-42)-OH (SEQ ED NO:94);
  • Example 92 (Pro 3 , A5c u , Nle l4 )hGEP(l -3O)-OH (SEQ ED NO:95);
  • Example 93 (Aib 2 , A6c 7 , Gln 43 )hGEP(l-43)-OH (SEQ ED NO:96);
  • Example 94 [Aib 2 , A6c 7 , Cys(Psu) 32 ]hGEP(l-42)-OH (SEQ ED NO:97);
  • Example 96 (Pro 3 , A5c ⁇ , A6c 14 )hGEP(l -3O)-NH 2 (SEQ ED NO:99);
  • Example 97 (Pro 3 , A6c 7 )hGEP(l -3O)-NH 2 (SEQ ED NO:100);
  • Example 98 (Pro 3 , A5c u )hGEP(l-30)-NH 2 (SEQ ID NO: 101);
  • Example 99 [Aib 2 , A6c 7 , Cys(Psu) 33 ]hGEP(l-42)-OH (SEQ ED NO: 102);
  • Example 100 [Aib 2 , A6c 7 , Cys(Psu) 37 ]hGEP(l-42)-OH (SEQ ED NO: 103);
  • Example 101 (4Hppa', Aib 13 )hGEP(l-42)-OH (SEQ ED NO: 104);
  • Example 102 (Pro 3 , A5c ⁇ , A6c l4 )hGEP(l-42)-OH (SEQ ED NO: 105);
  • Example 103 [Orn 1 (N-C(O)-(CH 2 ) 12 -CH 3 ), A6c 7 ]hGEP(l-42)-OH (SEQ ED NO: 106);
  • Example 104 (D-AIa 2 , A5c 1 M0 )hGIP(l-42)-OH;
  • Example 105 (D-AIa 2 , A5c", His 43 )hGEP(l-43)-OH;
  • Example 106 (D-AIa 2 , A5c 1 M1 )hGEP(l-42)-OH;
  • Example 107 (D-AIa 2 , A6c"' 14> 41 )hGIP(l-42)-OH;
  • Example 108 (Aib 2> 13 , Pro 3 , Nle 14 )hGEP(l -3O)-NH 2 (SEQ ED NO: 107);
  • Example 109 (Aib 2 , Pro 3 , A6c 7 )hGEP( 1-3 O)-NH 2 (SEQ ED NO: 108);
  • Example 110 (Aib 2 , Pro 3 , A5c n )hGEP(l-30)-NH 2 (SEQ ED NO: 109);
  • Example 111 (Aib 2 , Pro 3 , A5c", Nle 14 )hGEP(l -3O)-NH 2 (SEQ ED NO: 1 10);
  • Example 112 (Aib 2 , Pro 3 , A5c ⁇ , A6c 14 )hGEP(l -3O)-NH 2 (SEQ ED NO: 111);
  • Example 113 (NMe-Tyr 1 , Aib 2 , A5c u , Nle 14 )hGIP(l-42)-OH (SEQ ED NO: 112);
  • Example 114 (GIy 2 , A6c 11 14 41 )hGEP(l-42)-OH (SEQ ED NO: 113);
  • Example 115 (GIy 2 , Aib 13 , A5c 40 )hGEP(l-42)-OH (SEQ ED NO: 114);
  • Example 116 (GIy 2 , A5c" l 41 )hGEP(l-42)-OH (SEQ ED NO: 115);
  • Example 117 (GIy 2 , A5c u , His 43 )hGIP(l-43)-OH (SEQ ID NO: 116);
  • Example 119 (D-AIa 2 , A5c n , NIe 14 , His 43 )hGIP(l-43)-OH;
  • Example 120 (D-AIa 2 , A5c ⁇ ' M , His 43 )hGIP(l-43)-OH;
  • Example 121 (D-AIa 2 , A5c"' 14 )hGIP(l-30)-NH 2 ;
  • Example 122 (D-AIa 2 , A5c ⁇ , His 31 )hGIP(l-31)-NH 2 ;
  • Example 123 (Aib 2 , A5c n ' 14 , His 43 )hGIP(l-43)-OH (SEQ ID NO:118).
  • a compound according to the present invention as summarized hereinabove and claimed in the appended claims may further compose a covalently linked PEG moiety, in which said PEG moiety is covalently linked to the compound via a Cys(maleimide), hCys(maleimide), or Pen(maleimide) linker, to form Cys(succmimide-N-PEG), hCys(succmimide-N-PEG), or Pen(succinimide-N-PEG), wherein "succmimide-N-PEG” is either linear or branched as defined hereinbelow.
  • Such PEG moiety has average molecular weight of from about 2,000 to about 80,000, and preferably such PEG moiety is selected from the group consisting of 5K PEG, 1OK PEG, 2OK PEG, 30K PEG, 40K PEG, 50K PEG, and 6OK PEG, to form
  • PEGylation occurs at any one of amino acid residue positions 16, 30, and 31-43, and preferably at any one of amino acid residue positions 32, 33 and 43, whereby Cys(succimmide-N- PEG), hCys(succinimide-N-PEG), or Pen(succinimide-N-PEG) is placed in any one of such amino acid residue positions.
  • the above formula (I) may be expanded to provide PEGylation sites at positions A 44 - A 47 .
  • the C-terminus of such PEGylated compounds of the present invention may be amidated, e g , (Aib 2> ") hGEP(l-42)-NH 2 (SEQ ID NO: 119), or it may remain as free acid, e g , (Aib 2 ' 11 JhGIP(I -42)- OH (SEQ ID NO:4).
  • A3c 1 -amino- 1 -cyclopropanecarboxyhc acid
  • A4c 1 -amino- 1 -cyclobutanecarboxylic acid
  • A5c 1 -amino- 1 -cyclopentanecarboxylic acid
  • A6c 1 -amino- 1 -cyclohexanecarboxylic acid
  • Ado 12-aminododecanoic acid
  • NMe-Tyr N-methyl-tyrosine
  • valine other abbreviations used herein are defined as follows:
  • BSA bovine serum albumin
  • DIPEA diisopropylethyl amine
  • 5K PEG polyethylene glycol, which may include other functional groups or moieties such as a linker, and which is either linear or branched as defined hereinbelow, with an average total molecular weight of about 5,000
  • 1OK PEG polyethylene glycol, which may include other functional groups or moieties such as a linker, and which is either linear or branched as defined hereinbelow, with an average total molecular weight of about 10,000
  • 20K PEG polyethylene glycol, which may include other functional groups or moieties such as a linker, and which is either linear or branched as defined hereinbelow, with an average total molecular weight of about 20,000
  • 30K PEG polyethylene glycol, which may include other functional groups or moieties such as a linker, and which is either linear or branched as defined hereinbelow, with an average total molecular weight of about 30,000
  • PEG polyethylene glycol, which may include other functional groups or moieties such as a linker, and which is either linear or branched as defined hereinbelow, with an average total molecular weight of about 40,000
  • PEG polyethylene glycol, which may include other functional groups or moieties such as a linker, and which is either linear or branched as defined hereinbelow, with an average total molecular weight of about 50,000
  • 6OK PEG polyethylene glycol, which may include other functional groups or moieties such as a linker, and which is either linear or branched as defined hereinbelow, with an average total molecular weight of about 60,000 tBu: tert-buty ⁇
  • TIS triisopropylsilane
  • Trt trityl
  • Pen(succinimide-N-PEG) has the structure of: "Cys(succinimide-N-(CH 2 ) 2 -C(O)NH-(CH 2 ) 3 -PEG)” has the structure of:
  • (Ci-C 30 )hydrocarbon moiety encompasses alkyl, alkenyl and alkynyl, and in the case of alkenyl and alkynyl there are C 2 -C 30 .
  • a peptide of this invention is also denoted herein by another format, e.g., (A5c 2 )hGIP(l-42)- OH (SEQ ID NO:3), with the substituted amino acids from the natural sequence placed between the brackets (e.g., A5c 2 for Ala 2 in hGIP).
  • the numbers between the parentheses refer to the number of amino acids present in the peptide (e.g., hGIP(l-42)-OH (SEQ ID NO: 1) is amino acids 1 through 42 of the peptide sequence for hGIP).
  • hGIP(l -3O)-NH 2 indicates that the C-terminus of the peptide is amidated; hGIP(l-42) (SEQ ID NO: 1) or hGIP(l-42)- OH (SEQ ID NO: 1) means that the C-terminus is the free acid.
  • hGIP Human GIP
  • Alkyl refers to R"-C(O)-, where R" is H, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, aryl, alkylaryl, or substituted alkylaryl.
  • R is H, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, aryl, alkylaryl, or substituted alkylaryl.
  • Alkyl refers to a hydrocarbon group containing one or more carbon atoms, where multiple carbon atoms if present are joined by single bonds. The alkyl hydrocarbon group may be straight- chain or contain one or more branches or cyclic groups.
  • Substituted alkyl refers to an alkyl wherein one or more hydrogen atoms of the hydrocarbon group are replaced with one or more substituents selected from the group consisting of halogen, (i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN, -SH, -NH 2 , -NHCH 3 , -NO 2 , -Ci -20 alkyl substituted with halogens, -CF 3 , -OCH 3 , -OCF 3 , and -(CH 2 ) 0 - 20 -COOH. In different embodiments 1, 2, 3 or 4 substituents are present.
  • halogen i.e., fluorine, chlorine, bromine, and iodine
  • alkyl acids containing, or consisting of, -(CH 2 ) 0-20 -COOH include 2-norbornane acetic acid, tert-buty ⁇ ic acid and 3-cyclopentyl propionic acid.
  • Heteroalkyl refers to an alkyl wherein one of more of the carbon atoms in the hydrocarbon group are replaced with one or more of the following groups: amino, amido, -O-, -S- or carbonyl. In different embodiments 1 or 2 heteroatoms are present.
  • Substituted heteroalkyl refers to a heteroalkyl wherein one or more hydrogen atoms of the hydrocarbon group are replaced with one or more substituents selected from the group consisting of halogen, -OH, -CN, -SH, -NH 2 , -NHCH 3 , -NO 2 , -C 1-20 alkyl substituted with halogens, -CF 3 , -OCH 3 , -OCF 3 , and -(CH 2 ) 0-20 -COOH. In different embodiments 1, 2, 3 or 4 substituents are present.
  • alkenyl refers to a hydrocarbon group made up of two or more carbons wherein one or more carbon-carbon double bonds are present.
  • the alkenyl hydrocarbon group may be straight-chain or contain one or more branches or cyclic groups.
  • Substituted alkenyl refers to an alkenyl wherein one or more hydrogens are replaced with one or more substituents selected from the group consisting of halogen, -OH, -CN, -SH, -NH 2 , -NHCH 3 , -NO 2 , -C 1-20 alkyl substituted with halogens, -CF 3 , -OCH 3 , -OCF 3 , and -(CH 2 V 20 -COOH. In different embodiments 1, 2, 3 or 4 substituents are present.
  • Aryl refers to an optionally substituted aromatic group with at least one ring having a conjugated pi-electron system, containing up to three conjugated or fused ring systems.
  • Aryl includes carbocyclic aryl, heterocyclic aryl and biaryl groups.
  • the aryl is a 5 or 6 membered ring.
  • Preferred atoms for a heterocyclic aryl are one or more sulfur, oxygen, and/or nitrogen.
  • Examples of aryl include phenyl, 1-naphthyl, 2-naphthyl, indole, quinoline, 2-imidazole, and 9-anthracene.
  • Aryl substituents are selected from the group consisting of -Ci -2O alkyl, -Ci -2 O alkoxy, halogen, -OH, -CN, -SH, -NH 2 , -NO 2 , -C,. 2O alkyl substituted with halogens, -CF 3 , -OCF 3 , and -(CH 2 ) O-2O -COOH.
  • the aryl contains 0, 1,2, 3, or 4 substituents.
  • Alkylaryl refers to an “alkyl” joined to an “aryl”.
  • the coupling time is 2 hrs for these residues and the residue immediately following them.
  • the substituents R 2 and R 3 of the above generic formula can be attached to the free amine of the N-terminal amino acid A 1 by standard methods known in the art.
  • alkyl groups e.g., (Ci-C 30 )alkyl
  • Hydroxyalkyl groups e.g., (C r C 30 )hydroxyalkyl
  • Acyl groups e.g., -C(O)X 3
  • Solid-phase peptide synthesis was used to assemble the peptide using microwave-assisted Fmoc Chemistry on a Liberty Peptide Synthesizer (CEM; Matthews, NC, USA) at the 0.1 mmole scale.
  • Pre-loaded Fmoc-Gln(Trt)-Wang resin (0.59 mmole/g; Novabiochem, San Diego, CA, USA) was used to generate the C-terminal acid peptide.
  • the resin (0.17 g) was placed in a 50 ml conical tube along with 15 ml of dimethylformamide (DMF) and loaded onto a resin position on the synthesizer. The resin was then quantitatively transferred to the reaction vessel via the automated process.
  • DMF dimethylformamide
  • the standard Liberty synthesis protocol for 0.1 mmole scale synthesis was used. This protocol involved deprotectmg the N-termmal Fmoc moiety via an initial treatment with 7 ml of 20% pipe ⁇ dme, containing 0.1M N-hydroxybenzot ⁇ azole (HOBT), in DMF. The initial deprotection step was for 30 seconds with microwave power (45 watts, maximum temperature of 75 0 C), and nitrogen bubbling (3 seconds on / 7 seconds off). The reaction vessel was then drained and a second pipe ⁇ dine treatment, identical to the first treatment, except that it was for a 3 -minute duration. The resm was then drained and thoroughly washed with DMF several times.
  • HOBT N-hydroxybenzot ⁇ azole
  • the protected ammo acid, Fmoc- Thr(tBu)-OH prepared as 0.2M stock solution in DMF, was then added (2.5 ml, 5 eq.), followed by 1.0 ml of 0.45M (4.5 eq.) HBTU [2-(lH-benzo-t ⁇ azole-l-yl)-l,l,3,3-tetramethyluromum hexafluorophosaphate] in DMF. This was followed by the addition of 0.5 ml of 2M (10 eq.) DIPEA (dnsopropylethylamme) in NMP (N-methylpyrrollidmone). The coupling step was performed for 5 minutes using 20 watts of microwave power, a max temperature of 75 0 C, and the same rate of nitrogen bubbling.
  • Cycle 2 was then initiated similar to cycle 1. All ammo acids were introduced similarly and a double-coupling strategy was employed throughout the entire sequence. Cycles 1-3, 19-20, 25-26, and 30-39 contained a capping procedure immediately following the coupling step.
  • Capping was performed by adding 7 ml of 0.5M acetic anhydride, containing 0.015M HOBT in NMP, along with 2 ml of the 2M DIPEA solution using a multi-step microwave protocol: 50 watts of power for 30 seconds (65 0 C max temperature), followed by 30 seconds of microwave power off, followed by a second round of 30 seconds of microwave power on (50 watts), and then again 30 seconds of no microwave power. The resin was then drained and thoroughly washed with DMF.
  • Cycle 1 Fmoc-Cys(Trt)-OH
  • Cycle 2 Fmoc-Ile-OH
  • Cycle 3 Fmoc-Asn(Trt)-OH
  • Cycle 4 Fmoc-His(Trt)-OH
  • Cycle 5 Fmoc- Lys(Boc)-OH
  • Cycle 6 Fmoc-Trp(Boc)-OH
  • Cycle 7 Fmoc-Asp(OtBu)-OH
  • Cycle 8 Fmoc- Asn(Trt)-OH
  • Cycle 9 Fmoc-Lys(Boc)-OH
  • Cycle 10 Fmoc-Lys(Boc)-OH
  • Cycle 11 Fmoc-Gly-OH
  • Cycle 12 Fmoc-Lys(Boc)-OH
  • Cycle 13 Fmoc-Gln(Trt)-OH
  • the coupling protocol for Fmoc-His(Trt)-OH was a slightly modified version of the standard protocol.
  • the microwave power was off for the first 2 minutes, followed by 4 minutes with microwave power on (20 watts; max temperature of 50 0 C).
  • microwave power on (20 watts; max temperature of 50 0 C).
  • standard piperidine treatment was used to remove the N- terminal Fmoc group.
  • the resin was then thoroughly washed with DMF and then transferred back to the 50 ml conical tube using DMF as the transfer solvent.
  • the resin was deprotected and cleaved from the resin via treatment with 5 ml of the following reagent: 5% TIS, 2% water, 5% (w/v) dithiothrieitol (DTT), 88% TFA, and allowed to mix for 3.5 hours.
  • the filtrate was collected into 45 ml of cold anhydrous ethyl ether.
  • the precipitate was pelleted for 10 minutes at 3500 RPM in a refrigerated centrifuge.
  • the ether was decanted, and the peptide re-suspended in fresh ether.
  • the ether workup was performed a total of 2 times. Following the last ether wash, the peptide was allowed to air dry to remove residual ether.
  • the peptide pellet was resuspended in 8 ml of acetonitrile (Acn) followed by 8 ml of de-ionized water, and allowed to fully dissolve. The peptide solution was then analyzed by mass spectrometry. Mass analysis employing electrospray ionization identified a main product containing a mass of 5011.7 Daltons; corresponding to the desired linear product. The crude product (approximately 500 mg) was analysed by HPLC, employing a 250 x 4.6 mm Cl 8 column (Phenomenex; Torrance, CA, USA) using a gradient of 2-80% acetonitrile (0.1% TFA) over 30 minutes. Analytical HPLC identified a product with 34% purity.
  • the crude peptide was then purified on a preparative HPLC equipped with a Cl 8 reverse phase column using a 10-60% acetonirile (0.1% TFA) over 50 minutes at a 10 ml/min flowrate.
  • the purified peptide was then lyophilized yielding 15 mg of peptide.
  • the linear peptide was then derivatized with N-propylmaleimide (Pma) to generate the propylsuccinimide (Psu) derivative on the Cysteine side chain.
  • the purified linear peptide was brought up in water, adjusted to pH 6.5 with ammonium carbonate, at 5 mg/ml. Five equivalents of Pma was added with constant stirring for 30 seconds.
  • the derivatized peptide solution was then analyzed by mass spectrometry.
  • Mass analysis employing electrospray ionization identified a main product containing a mass of 5150.7 Daltons; corresponding to the desired Psu derivatized product.
  • the product was then re- purified via preparative HPLC using a similar gradient as before.
  • the purified product was analyzed by HPLC for purity (95.10%) and mass spectrometry (5150.9 Daltons) and subsequently lyophilized.
  • Example 103 r ⁇ m' (N-C(OV(CH 2 ) n -CHO. A6c 7 lhGIPO -42VOH
  • Solid-phase peptide synthesis was used to assemble the peptide using microwave-assisted Fmoc Chemistry on a Liberty Peptide Synthesizer (CEM; Matthews, NC, USA) at the 0.1 mmole scale.
  • Pre-loaded Fmoc-Gln(Trt)-Wang resin (0.59 mmole/g; Novabiochem, San Diego, CA, USA) was used to generate the C-terminal acid peptide.
  • the resin (0.17 g) was placed in a 50 ml conical tube along with 15 ml of dimethylfbrrnamide (DMF) and loaded onto a resin position on the synthesizer. The resin was then quantitatively transferred to the reaction vessel via the automated process.
  • DMF dimethylfbrrnamide
  • the standard Liberty synthesis protocol for 0.1 mmole scale synthesis was used. This protocol involves deprotecting the N-terminal Fmoc moiety via an initial treatment with 7 ml of 20% piperidine, containing 0.1M N-hydroxybenzotriazole (HOBT), in DMF. The initial deprotection step was for 30 seconds with microwave power (45 watts, maximum temperature of 75 0 C), and nitrogen bubbling (3 seconds on / 7 seconds off). The reaction vessel was then drained and a second piperidine treatment, identical to the first treatment, except that it was for a 3 -minute duration. The resin was then drained and thoroughly washed with DMF several times.
  • HOBT N-hydroxybenzotriazole
  • the protected amino acid, Fmoc- Thr(tBu)-OH prepared as 0.2M stock solution in DMF, was then added (2.5 ml, 5 eq.), followed by 1.0 ml of 0.45M (4.5 eq.) HBTU [2-(lH-benzo-triazole-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosaphate] in DMF. This was followed by the addition of 0.5 ml of 2M (10 eq.) DIPEA (diisopropylethylamine) in NMP (N-methylpyrrollidinone). The coupling step was performed for 5 minutes using 20 watts of microwave power, a max temperature of 75 0 C, and the same rate of nitrogen bubbling.
  • DIPEA diisopropylethylamine
  • Cycle 2 was then initiated similar to cycle 1. All amino acids were introduced similarly and a double-coupling strategy was employed throughout the entire sequence. Cycles 1-3, 19-20, 25-26, and 30-39 contained a capping procedure immediately following the coupling step.
  • Capping was performed by adding 7 ml of 0.5M acetic anhydride, containing 0.015M HOBT in NMP, along with 2 ml of the 2M DDPEA solution using a multi-step microwave protocol: 50 watts of power for 30 seconds (65 0 C max temperature), followed by 30 seconds of microwave power off, followed by a second round of 30 seconds of microwave power on (50 watts), and then again 30 seconds of no microwave power. The resin was then drained and thoroughly washed with DMF.
  • Cycle 1 Fmoc-Thr(tBu)-OH
  • Cycle 2 FmOC-Be-OH
  • Cycle 3 Fmoc-Asn(Trt)-OH
  • Cycle 4 Fmoc-His(Trt)-OH
  • Cycle 5 Fmoc- Lys(Boc)-OH
  • Cycle 6 Fmoc-Trp(Boc)-OH
  • Cycle 7 Fmoc-Orn(Mtt)-OH
  • Cycle 8 Fmoc-Asn(Trt)- OH
  • Cycle 9 Fmoc-Lys(Boc)-OH
  • Cycle 10 Fmoc-Lys(Boc)-OH
  • Cycle 11 Fmoc-Gly-OH
  • Cycle 12 Fmoc-Lys(Boc)-OH
  • Cycle 13 Fmoc-Gln(Trt)-OH
  • Cycle 14 Fmoc-Gln(Trt)-OH
  • the coupling protocol for Fmoc-His(Trt)-OH was a slightly modified version of the standard protocol.
  • the microwave power was off for the first 2 minutes, followed by 4 minutes with microwave power on (20 watts; max temperature of 50 0 C).
  • the resin was treated with 12 ml of 1% trifluoroacetic acid (TFA) / 5% triisopropylsilane (TIS) in dichloromethane (DCM) for 5 minutes and a N 2 sparge rate of 5 seconds on and 10 seconds off.
  • TFA trifluoroacetic acid
  • TIS triisopropylsilane
  • the resin was deprotected and cleaved from the resin via treatment with 5 ml of the following reagent: 5% TIS, 2% water, 5% (w/v) dithiothrieitol (DTT), 88% TFA, and allowed to mix for 3.5 hours.
  • the filtrate was collected into 45 ml of cold anhydrous ethyl ether.
  • the precipitate was pelleted for 10 minutes at 3500 RPM in a refrigerated centrifuge.
  • the ether was decanted, and the peptide re-suspended in fresh ether.
  • the ether workup was performed a total of 2 times. Following the last ether wash the peptide was allowed to air dry to remove residual ether.
  • the peptide pellet was resuspended in 8 ml of acetonitrile (Acn) followed by 8 ml of de-ionized water, and allowed to fully dissolve. The peptide solution was then analyzed by mass spectrometry. Mass analysis employing electrospray ionization identified a main product containing a mass of 5205.1 Daltons; corresponding to the desired linear product. The crude product (approximately 500 mg) was analysed by HPLC, employing a 250 x 4.6 mm Cl 8 column (Phenomenex; Torrance, CA, USA) using a gradient of 2- 80% acetonitrile (0.1% TFA) over 30 minutes. Analytical HPLC identified a product with 50% purity.
  • the peptide was then purified on a preparative HPLC equipped with a Cl 8 column using a similar elution gradient.
  • the purified product was re-analyzed by HPLC for purity (96.10%) and mass spectrometry (5204.6 Daltons) and subsequently lyophilized. Following lyophillization, 6.2 mg of purified product was obtained representing a 1.2% yield.
  • the PEGylated GIP compounds disclosed herein can be synthesized substantially according to the procedure described for the synthesis of the compound of Example 15, by using PEG- maleimide as the starting material instead of N-propylmaleimide used in Example 15.
  • Membranes for in vitro receptor binding assays were prepared by homogenizing the CHO-Kl clonal cells expressing the human recombinant GIP receptor, with a Brinkman Polytron (setting 6, 15 sec), in ice-cold 5OmM Tris-HCl and then subjected to two centrifugations at 39,000 g for 10 minutes, with a resuspension in fresh buffer in between.
  • aliquots of the washed membrane preparations were incubated (100 minutes at 25 0 C with 0.05nM [ 125 I]GIP (approximately 2200 Ci/mmol) in 5OmM Tris-HCl, 0.1 mg/ml bacitracin, and 0.1% BSA.
  • the final assay volume was 0.5 ml.
  • the incubations were terminated by rapid filtration through GF/C filters (pre-soaked in 0.5% polyethylenimine) using a Brandel filtration manifold. Each tube and filter were then washed three times with 5-ml aliquots of ice-cold buffer. Specific binding was defined as the total radioligand bound minus that bound in the presence of 100OnM GIP. In vitro hGIP receptor binding data for the compounds exemplified herein are given in Table 2.
  • GIP peptide 50 ⁇ L 1 mg/ml was added to 450 ⁇ L plasma (human or rat), vertexed briefly and incubated at 37 0 C. 50 ⁇ L was removed at various times, like at 0, 1, 2, 3, 4, 8, 24, 32, 48, 56, 72 hours, mixed with 5 ⁇ L formic acid and 150 ⁇ L acetonitrile in a microcentrifuge tube, vertexed, and centrifuged for 10 minutes at 1OK rpm. The supernatant was transferred to an injection vial and analyzed by LC-MS.
  • the LC-MS system consisted of an API4000 mass spectrometer with an ESI probe. Positive ion mode and full scan detection were used.
  • HPLC separation was carried out on a Luna 3 ⁇ C8 (2), 2 x 30 mm column with a gradient from 90% A to 90% B in 10 minutes at a flow rate of 0.3 ml/min.
  • Buffer A was 1% formic acid in water and buffer B was 1% formic acid acetonitrile.
  • Human and rat plasma half-life data for the compounds exemplified herein are given in Table 2.
  • mice Male Sprague Dawley rats with a body weight of approximately 275-300 g were used as experimental subjects. The day prior to the treatment, right atrial cannulae were implanted via the jugular vein under chlorohydrate. Each cannula was filled with 100 u/ml heparin saline and tied. The rats were fasted for approximately 18 hours prior to dosing with the compound or the vehicle (saline/0.25% BSA). The day of the experiment, aliquots of compound were thawed, brought to room temperature and vortexed thoroughly. A careful check was made for any sign of compound coming out of solution.
  • a 500 ⁇ l blood sample was withdrawn and replaced with an equal volume of heparinized saline (10 u/ml).
  • a 500 ⁇ l blood sample was withdrawn through the cannula.
  • either the vehicle or the appropriate dose of the compound was injected into the cannula and pushed in with the glucose (1 g/kg) or vehicle solution.
  • 500 ⁇ l of volume of heparinized saline (10 u/ml) was used to push in the remaining glucose through the cannula.
  • the peptides of this invention can be provided in the form of pharmaceutically acceptable salts.
  • such salts include, but are not limited to, those formed with organic acids (e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, methanesulfonic, toluenesulfonic, or pamoic acid), inorganic acids (e.g., hydrochloric acid, sulfuric acid, or phosphoric acid), and polymeric acids (e.g., tannic acid, carboxymethyl cellulose, polylactic, polyglycolic, or copolymers of polylactic-glycolic acids).
  • organic acids e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, methanesulfonic, toluenesulfonic, or pamoic acid
  • inorganic acids e.g., hydrochloric acid, sulfuric acid, or
  • a typical method of making a salt of a peptide of the present invention is well known in the art and can be accomplished by standard methods of salt exchange. Accordingly, the TFA salt of a peptide of the present invention (the TFA salt results from the purification of the peptide by using preparative HPLC, eluting with TFA containing buffer solutions) can be converted into another salt, such as an acetate salt by dissolving the peptide in a small amount of 0.25 N acetic acid aqueous solution. The resulting solution is applied to a semi-prep HPLC column (Zorbax, 300 SB, C-8).
  • the column is eluted with (1) 0.1N ammonium acetate aqueous solution for 0.5 hrs, (2) 0.25N acetic acid aqueous solution for 0.5 hrs, and (3) a linear gradient (20% to 100% of solution B over 30 minutes) at a flow rate of 4 ml/min (solution A is 0.25N acetic acid aqueous solution; solution B is 0.25N acetic acid in acetonitrile/water, 80:20).
  • solution A is 0.25N acetic acid aqueous solution
  • solution B is 0.25N acetic acid in acetonitrile/water, 80:20.
  • the fractions containing the peptide are collected and lyophilized to dryness.
  • the dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained.
  • the selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment.
  • an effective dosage for the activities of this invention is in the range of 1 x 10 "7 to 200 mg/kg/day, preferably 1 x 10 "4 to 100 mg/kg/day, which can be administered as a single dose or divided into multiple doses.
  • the compounds of this invention can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual, or topical routes of administration, and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.
  • parenteral e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant
  • nasal, vaginal, rectal, sublingual, or topical routes of administration and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
  • the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch.
  • Such dosage forms can also comprise, as is normal practice, additional substances other than such inert diluents, e.g. , lubricating agents such as magnesium stearate.
  • the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
  • Liquid dosage forms for oral administration include, without limitation, pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, and the like, containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.
  • Preparations according to this invention for parenteral administration include, without limitation, sterile aqueous or non-aqueous solutions, suspensions, emulsions, and the like.
  • non-aqueous solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate.
  • Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
  • compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as coca butter or a suppository wax.
  • Compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.
  • a compound of this invention can be administered in a sustained release composition such as those described in the following patents and patent applications.
  • U.S. Patent No. 5,672,659 teaches sustained release compositions comprising a bioactive agent and a polyester.
  • U.S. Patent No. 5,595,760 teaches sustained release compositions comprising a bioactive agent in a gelable form.
  • U.S. Patent No. 5,821,221 teaches polymeric sustained release compositions comprising a bioactive agent and chitosan.
  • U.S. Patent No.5,916,883 teaches sustained release compositions comprising a bioactive agent and cyclodextrin.
  • PCT publication WO99/38536 teaches absorbable sustained release compositions of a bioactive agent.
  • PCT publication WO00/04916 teaches a process for making microparticles comprising a therapeutic agent such as a peptide in an oil-in-water process.
  • PCT publication WO00/09166 teaches complexes comprising a therapeutic agent such as a peptide and a phosphorylated polymer.
  • PCT publication WO00/25826 teaches complexes comprising a therapeutic agent such as a peptide and a polymer bearing a non-polymerizable lactone.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP- receptor agonists or antagonists for treatment of GIP -receptor mediated conditions, such as non- insulin dependent diabetes mellitus and obesity.

Description

ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE
FIELD OF THE INVENTION The present invention relates to the area of novel analogues of glucose-dependent insulinotropic polypeptide, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.
BACKGROUND ART
Glucose-dependent insulinotropic polypeptide ("GIP", also known as "gastric inhibitory polypeptide"; SEQ ID NO: 1) is a 42 -residue peptide secreted by enteroendorine K-cells of the small intestine into the bloodstream in response to oral nutrient ingestion. GIP inhibits the secretion of gastric acid, and it has been shown to be a potent stimulant for the secretion of insulin from pancreatic beta cells after oral glucose ingestion (the "incretin effect") (Creutzfeldt, W., et al, 1979, Diabetologia, 16:75-85).
Insulin release induced by the ingestion of glucose and other nutrients is due to both hormonal and neural factors (Creutzfeldt, W., et al, 1985, Diabetologia, 28:565-573). Several gastrointestinal regulatory peptides have been proposed as incretins, and among these candidates, only GIP and glucagon-like peptide 1 ("GLP-I") appear to fulfill the requirements to be considered physiological stimulants of postprandial insulin release (Nauck, et al, 1989, J. Clin. Endorinol. Metab., 69:654- 662). It has been shown that the combined effects of GIP and GLP-I are sufficient to explain the full incretin effect of the enteroinsular axis (Fehmann, H. C, et al, 1989, FEBS Lett., 252: 109-112).
As is well known to those skilled in the art, the known and potential uses of GIP are varied and multitudinous. Thus, the administration of the compounds of this invention for purposes of eliciting an agonist effect can have the same effects and uses as GIP itself. These varied uses of GIP may be summarized as follows: treating a disease selected from the group consisting of type 1 diabetes, type 2 diabetes (Visboll, T., 2004, Dan. Med. Bull, 51 :364-70), insulin resistance (WO 2005/082928), obesity (Green, B. D., et al, 2004, Current Pharmaceutical Design, 10:3651-3662), metabolic disorder (Gault, V. A., et al, 2003, Biochem. Biophys. Res. Commun., 308:207-213), central nervous system disease, neurodegenerative disease, congestive heart failure, hypoglycemia, and disorders wherein the reduction of food intake and weight loss are desired. In pancreatic islets, GIP not only enhances insulin secretion acutely, but it also stimulates insulin production through enhancement of proinsulin transcription and translation (Wang, et al, 1996, MoI. Cell. Endocrinol, 116:81-87) and enhances the growth and survival of pancreatic beta cells (Trumper, et al, 2003,
Diabetes, 52:741-750). In addition to effects on the pancreas to enhance insulin secretion, GIP also has effects on insulin target tissues directly to lower plasma glucose: enhancement of glucose uptake in adipose (Eckel, et al, 1979, Diabetes, 28: 1141-1142) and muscle (O'Harte, et al, 1998, J. Endocrinol., 156:237-243), and inhibition of hepatic glucose production (Elahi, D., et al, 1986, Can. J. Physiol. Pharmacol., 65: Al 8). In addition, a GIP receptor antagonist in accordance with the present invention inhibits, blocks or reduces glucose absorption from the intestine of an animal. In accordance with this observation, therapeutic compositions containing GIP antagonists may be used in patients with non- insulin dependent diabetes mellitus to improve tolerance to oral glucose in mammals, such as humans, to prevent, inhibit or reduce obesity by inhibiting, blocking or reducing glucose absorption from the intestine of the mammal.
The use of unmodified GIP as a therapeutic, however, is limited by the short in vivo half-life of about 2 minutes (Said and Mutt, 1970, Science, 169: 1217-1218). In serum, both incretins, GIP and GLP-I, are degraded by dipeptidyl peptidase IV ("DPPIV"). Improving the stability of GIP to proteolysis not only maintains the activity of GIP at its receptor but, more importantly, prevents the production of GIP fragments, some of which act as GIP receptor antagonists (Gault, et al., 2002, J. Endocrinol, 175:525-533). Reported modifications have included protection of the N-terminus of GIP from proteolysis by DPPIV through modification of the N-terminal tyrosine (O'Harte, et al, 2002, Diabetologia, 45:1281-1291), mutation of the alanine at position 2 (Hinke, et al, 2002, Diabetes, 51 :656-661), mutation of glutamic acid at position 3 (Gault, et al, 2003, Biochem. Biophys. Res. Commun., 308:207-213), and mutation of alanine at position 13 (Gault, et al, 2003, Cell Biol. International, 27:41-46),
The following patent applications have been filed related to the effects of GIP analogues on the function of various target organs and their potential use as therapeutic agents:
PCT publication WO 00/58360 discloses peptidyl analogues of GIP which stimulate the release of insulin. In particular, this application discloses specific peptidyl analogues comprising at least 15 amino acid residues from the N-terminal end of GIP(I -42), e.g., an analogue of GIP containing exactly one amino acid substitution or modification at positions 1, 2 and 3, such as [Pro3]GIP(l-42).
PCT publication WO 98/24464 discloses an antagonist of GIP consisting essentially of a 24- amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP, a method of treating non-insulin dependent diabetes mellitus and a method of improving glucose tolerance in a non-insulin dependent diabetes mellitus patient.
PCT publication WO 03/082898 discloses C-terminal truncated fragments and N-terminal modified analogues of GEP, as well as various GEP analogues with a reduced peptide bond or alterations of the amino acids close to the DPPEV-specific cleavage site. This application further discloses analogues with different linkers between potential receptor binding sites of GIP. The compounds of this application are alleged to be useful in treating GlP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.
There exists a need for improved analogues of GIP, which are stable in formulation and have long plasma half-life in vivo resulting from decreased susceptibility to proteolysis and decreased clearance while maintaining binding affinity to a GIP receptor to elicit respective agonistic or antagonistic effects. Moreover, among other therapeutic effects of the compounds of the present invention as illustrated herein, tighter control of plasma glucose levels may prevent long-term diabetic complications, thereby providing an improved quality of life for patients.
SUMMARY OF THE INVENTION
In one aspect, the invention relates to peptide variants of GIP of the following formula (I):
(R2R3)-A1-A2-A3-A4-A5-A6-A7-A8-A9-A1O-AU-AI2-A13-A14-A15-A16-A17-A18-A19-A2O-A21-A22- A23-A2^A25-A26-A27-A2^A29-AM-A31-A32-A33-AM-A35-A3^A"-A38-A39-A40-A4I-A42-A43-RI ) (I) wherein:
A1 is Tyr, 4Hppa, or HN-CH((CH2)n-N(R4R5))-C(O);
A2 is Ala, Abu, D-Abu, Ace, Aib, β-Ala, D-AIa, Gaba, GIy, Ser, D-Ser, Thr, D-Thr, VaI, or D-VaI; A3 is GIu, Aib, Asp, NMe-Asp, Dhp, Dmt, GIu, NMe-GIu, 3Hyp, 4Hyp, 4Ktp, Pro, hPro, Thz, or Tic;
A4 is GIy, Ace, Aib, or β-Ala; A5 is Thr, Ace, Aib, or Ser;
A6 is Phe, Ace, Aib, Aic, Cha, INaI, 2NaI, 2-Pal, 3-Pal, 4-Pal, (X4,X5,X6,X7,X8)Phe, or Trp; A7 is lie, Abu, Ace, Aib, Ala, Cha, Leu, NIe, Phe, Tie, or VaI;
A8 is Ser, Aib, or Thr; A9 is Asp, Aib, or GIu;
A10 is Tyr, Ace, Cha, INaI, 2NaI, 2-Pal, 3-Pal, 4-Pal, Phe, or (X4,X5,X6,X7,X8)Phe; A11 is Ser, Ace, Aib, NIe, or Thr; A12 is He, Abu, Ace, Aib, Ala, Cha, Leu, NIe, Phe, Tie, or VaI;
A13 is Ala, Ace, Aib, β-Ala, D-AIa, GIy, or Ser; A14 is Met, Abu, Ace, Aib, Ala, Cha, He, Leu, NIe, Phe, Tie, or VaI; A15 is Asp, Aib, or GIu;
A16 is Lys, Amp, Ape, Arg, hArg, Orn, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N- alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH-
(CH2)y-CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)- NH-(CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)rCH3), hCys(succinimide-N-(CH2)s- NH-C(O)-(CH2)t-CH3), or Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3);
A17 is Ee, Abu, Ace, Aib, Ala, Cha, Leu, NIe, Phe, Tie, or VaI;
A18 is His, Amp, Arg, 2-Pal, 3-Pal, 4-Pal, Phe, or Tyr; A19 is GIn, Aib, or Asn;
A20 is GIn, Aib, or Asn;
A21 is Asp, Aib, or GIu;
A22 is Phe, Ace, Aib, Aic, Cha, INaI, 2NaI, 2-Pal, 3-Pal, 4-Pal, (X4,X5,X6,X7,X8)Phe, or Trp;
A23 is VaI, Abu, Ace, Aib, Ala, Cha, Ee, Leu, NIe, or Tie; A24 is Asn, Aib, or GIn;
A25 is Trp, Ace, Aib, INaI, 2NaI, 2-Pal, 3-Pal, 4-Pal, Phe, or (X4,X5,X6,X7,X8)Phe;
A26 is Leu, Ace, Aib, Cha, Ee, NIe, Phe, (X4,X5,X6,X7,X8)Phe, or Tie;
A27 is Leu, Ace, Aib, Cha, Be, NIe, Phe, (X4,X5,X6,X7,X8)Phe, or Tie,;
A28 is Ala, Ace, or Aib; A29 is GIn, Aib, Asn, or deleted;
A30 is Lys, Amp, Ape, Arg, hArg, Orn, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N- alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)- NH-(CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2),-CH3), hCys(succinimide-N-(CH2)s- NH-C(O)-(CH2)rCH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), or deleted;
A31 is GIy, Ace, Aib, β-Ala, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y- CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), hCys(succinimide-N-(CH2)s-NH- C(O)-(CH2),-CH3), His, Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)rCH3), or deleted;
A32 is Lys, Amp, Ape, Arg, hArg, Orn, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N- alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)- NH-(CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)rCH3), hCys(succinimide-N-(CH2)s- NH-C(O)-(CH2)t-CH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), or deleted;
A33 is Lys, Amp, Ape, Arg, hArg, Om, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N- alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)- NH-(CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)rCH3), hCys(succinimide-N-(CH2)s- NH-C(O)-(CH2)rCH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)rCH3), or deleted;
A34 is Asn, Aib, GIn, Ser, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y- CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2))C-C(O)-NH- (CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), hCys(succinimide-N-(CH2)s-NH- C(O)-(CH2)t-CH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)rCH3), or deleted;
A35 is Asp, Aib, GIu, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y- CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), hCys(succinimide-N-(CH2)s-NH- C(O)-(CH2)t-CH3), Pen(succmimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), or deleted;
A36 is Tip, Ace, Aib, INaI, 2NaI, 2-Pal, 3-Pal, 4-Pal, Phe, (X4,X5,X6,X7,X8)Phe, HN- CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide- N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), hCys(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Cys(succinimide-N-(CH2)S-NH- C(O)-(CH2X-CH3), hCys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), Pen(succinimide-N-(CH2)s- NH-C(O)-(CH2X-CH3), or deleted; A37 is Lys, Amp, Ape, Arg, hArg, Orn, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N- alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3)> Pen(succinimide-N-(CH2)x-C(O)- NH-(CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)rCH3), hCys(succinimide-N-(CH2)s- NH-C(O)-(CH2)t-CH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)rCH3), or deleted; A38 is His, Amp, 2-Pal, 3-Pal, 4-Pal, Phe, Tyr, HN-CH((CH2)n-N(R4R5))-C(O),
Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide- N-(CH2)x-C(O)-NH-(CH2)y-CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)rCH3), hCys(succinimide-N-(CH2)s-NH-C(O)-(CH2),-CH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)r CH3), or deleted;
A39 is Asn, Aib, GIn, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y- CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), hCys(succinimide-N-(CH2)s-NH- C(O)-(CH2X-CH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), or deleted;
A40 is He, Ace, Aib, Ser, Thr, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y- CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)rCH3), hCys(succinimide-N-(CH2)s-NH- C(O)-(CH2)t-CH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2),-CH3), or deleted;
A41 is Thr, Ace, Aib, Asn, GIn, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y- CH3), hCys(succinimide-N-(CH2)χ-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), Cys(succinimide-N-(CH2)s-NΗ-C(O)-(CH2)rCH3), hCys(succinimide-N-(CH2)s-NH- C(O)-(CH2)t-CH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), or deleted;
A42 is GIn, Ace, Aib, Asn, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y- CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3)) Pen(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3)) Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), hCys(succinimide-N-(CH2)s-NH- C(O)-(CH2)t-CH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), or deleted;
A43 is Ace, Aib, Ala, Asp, GIn, His, Phe, Thr, Tip, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide- N-(CH2)x-C(O)-NH-(CH2)y-CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), hCys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)t- CH3), or deleted; R1 is OH, NH2, (d-C30)alkoxy, or NH-X2-CH2-Z°, wherein X2 is a (C0-C30) hydrocarbon moiety and Z0 is H, OH, CO2H, or CONH2; each of R2, R3, R4 and R5 is independently selected from the group consisting of H, (Ci - C30)alkyl, (C,-C30)heteroalkyl, (C,-C30)acyl, (C2-C3O)alkenyl, (C2-C3O)alkynyl, aryl(Ci-C30)alkyl, aryl(Ci-C30)acyl, substituted (Ci-C30)alkyl, substituted (Ci-C30)heteroalkyl, substituted (Ci-C3o)acyl, substituted (C2-C30)alkenyl, substituted (C2-C30)alkynyl, substituted aryl(C]-C30)alkyl, and substituted aryl(Ci-C30)acyl; provided that when R2 is (Ci-C30)acyl, aryl(CrC30)acyl, substituted (CrC30)acyl, or substituted aryl(C,-C30)acyl, then R3 is H, (C,-C30)alkyl, (CrC30)heteroalkyl, (C2-C30)alkenyl, (C2- C30)alkynyl, aryl(Ci-C30)alkyl, substituted (CrC30)alkyl, substituted (CrC30)heteroalkyl, substituted (C2-C30)alkenyl, substituted (C2-C30)alkynyl, or substituted aryl(CrC3o)alkyl; further provided that when R4 is (C1-C30^CyI, aryl(Ci-C30)acyl, substituted (Ci-C30)acyl, or substituted aryl(Ci-C30)acyl, then R5 is H, (Ci-C30)alkyl, (C1-C30)heteroalkyl, (C2-C30)alkenyl, (C2-C30)alkynyl, aryl(C,-C30)alkyl, substituted (Ci-C30)alkyl, substituted (Ci-C30)heteroalkyl, substituted (C2-C30)alkenyl, substituted (C2- C30)alkynyl, or substituted aryl(CrC3o)alkyl; n is, independently for each occurrence, an integer from 1 to 5 inclusive; s, t, x and y each is, independently for each occurrence, an integer from 1 to 30 inclusive;
X4, X5, X6, X7 and X8 each is, independently for each occurrence, H, F, Cl, Br, I, (Ci.io)alkyl, substituted (CM0)alkyl, aryl, substituted aryl, OH, NH2, NO2, or CN; provided that when A1 is 4Hppa, then R2 and R3 are deleted; further provided that only one amino acid at positions 1, 2 and 3 of the compound is substituted or modified; and further provided that a compound of formula (I) is not (D-Ala2)hGIP(l-42), (Pro3)hGIP(l-42) (SEQ ID NO:120), (Aib3)hGIP(l-42) (SEQ ID NO: 121), (Ser2)hGIP(l-42) (SEQ ED NO:122), (Abu2)hGIP(l-42) (SEQ ID NO: 123), (D-Abu2)hGIP(l-42), (D-Ser2)hGIP(l-42), (D-Thr2)hGIP(l-42), or (D-Val2)hGIP(l-42).
A subset (A) of the compounds covered by the above formula (I) are those in which:
A1 is Tyr, 4HpPa, or Orn(N-C(O)-(CH2)12-CH3); A2 is Ala, A5c, A6c, Aib, D-AIa, GIy, or Ser;
A3 is GIu, Dhp, 3Hyp, 4Hyp, Pro, hPro, or Tic;
A4 is GIy or Aib;
A5 is Thr, A5c, or Aib;
A6 is Phe or A6c; A7 is He, A5c, A6c, or Aib;
A8 is Ser or Aib;
A9 is Asp or Aib;
A10 is Tyr;
A11 is Ser, A5c, A6c, Aib, or NIe; A12 is lie, A5c, or Aib;
A13 is Ala or Aib;
A14 is Met, A5c, A6c, or NIe;
A15 is Asp;
A16 is Lys; A17 is He or A6c;
A18 is His;
A19 is GIn;
A20 is GIn;
A21 is Asp; A22 is Phe;
A23 is VaI;
A24 is Asn;
A25 is Trp;
A26 is Leu or A6c; A27 is Leu or A6c;
A28 is Ala or Aib;
A29 is GIn;
A30 is Lys;
A31 is GIy, Aib, Cys(Psu), His, or deleted; A32 is Lys, Cys(Psu), or deleted;
A33 is Lys, Cys(Psu), or deleted;
A34 is Asn, Cys(Psu), or deleted; A35 is Asp, Cys(Psu), or deleted; A36 is Trp, Cys(Psu), or deleted; A37 is Lys, Cys(Psu), or deleted; A38 is His, Cys(Psu), or deleted; A39 is Asn, Cys(Psu), or deleted;
A40 IS Ee, A5c, A6c, Cys(Psu), or deleted; A41 is Thr, A5c, A6c, Aib, Cys(Psu), or deleted; A42 is GIn or deleted; A43 is Cys(Psu), GIn, His, or deleted, and provided that the compound contains at least one additional amino acid substitution or modification at positions 4-43.
A subset of the compounds of the preceding subset (A) are those in which A2 is D-AIa.
Another subset of the compounds of the preceding subset (A) are those in which A31 to A43 are deleted. Another subset of the compounds of the preceding subset (A) are those in which A2 is Ala,
A5c, A6c, or GIy; and A3 is GIu, Dhp, 3Hyp, 4Hyp, hPro, or Tic.
Another aspect of the present invention encompasses compounds consisting essentially of a sequence of the first 30 consecutive amino acid residues from the N-termmal end of the native hGIP ammo acid sequence, wherein the sequence comprises A5c, A6c, Aib, D-AIa, GIy or Ser substitution at position 2, and at least one additional ammo acid substitution or modification at positions 3-30.
A subset of the compounds of the immediately preceding aspect of the present invention are those in which A2 is Aib; A3 is Pro; and at least one of A7, A11, A13 and A14 is not the amino acid residue of the corresponding position in the native GIP.
Yet another aspect of the present invention encompasses GIP analogues comprising A5c, A6c, Aib, D-AIa, GIy or Ser substitution at position 2, and at least one additional amino acid substitution or modification at positions 1 and 3-42.
A subset of the compounds of the immediately preceding aspect of the present invention are those in which A2 is Aib.
Preferred compounds of formula (I) are: Example 1: (Aib2' π)hGIP(l-42)-0H (SEQ ID NO:4);
Example 2: (Aib2'9)hGIP(l-42)-OH (SEQ ID NO:5);
Example 3: (Aib2> 7)hGIP(l-42)-OH (SEQ ID NO:6);
Example 4: (Aib2> 5)hGIP(l -42)-OH (SEQ ID NO:7);
Example 5: (Aib2, A5c5)hGIP(l-42)-OH (SEQ ID NO: 8); Example 6: (Aib2, A5c7)hGIP(l -42)-OH (SEQ ID NO:9);
Example 7: (Aib2, A5c12)hGIP(l-42)-OH (SEQ ID NO: 10);
Example 8: (Aib2' 12)hGIP(l-42)-OH (SEQ ID NO: 11);
Example 9: (Aib2' 8)hGIP(l-42)-OH (SEQ ID NO: 12);
Example 10: (Aib2'4)hGIP(l-42)-OH (SEQ ED NO: 13);
Example 11: (Aib2, A5c5)hGIP(l -3O)-NH2 (SEQ ID NO: 14);
Example 12: (Aib2, A5c7)hGD?(l -3O)-NH2 (SEQ ID NO: 15);
Example 13: (Aib2, A5c12)hGIP(l -3O)-NH2 (SEQ ID NO: 16);
Example 14: (Aib2' 4)hGIP( 1-3 O)-NH2 (SEQ ID NO: 17);
Example 15: (Aib2' 5)hGIP(l -3O)-NH2 (SEQ ID NO: 18);
Example 16: (Aib2' 7)hGIP(l -3O)-NH2 (SEQ ID NO: 19);
Example 17: (Aib2' 8)hGIP(l -3O)-NH2 (SEQ ID NO:20);
Example 18: (Aib2' 9)hGIP(l -3O)-NH2 (SEQ ID NO:21);
Example 19: (Aib2' π)hGD?(l -3O)-NH2 (SEQ ID NO:22);
Example 20: (Aib2' 12)hGIP(l -3O)-NH2 (SEQ ID NO:23);
Example 21 : (Aib2' 13, A6c7, Nle14)hGD?(l-42)-OH (SEQ ID NO:24);
Example 22: (Aib2' 3I, A6c7)hGIP(l-42)-OH (SEQ ID NO:25);
Example 23: (Aib2'41, A6c7)hGIP(l-42)-OH (SEQ ID NO:26);
Example 24: (Aib2'31, A6c7, Nle14)hGC?(l-42)-OH (SEQ ID NO:27);
Example 25: (Aib2'41, A6c7, NleM)hGIP(l-42)-OH (SEQ ID NO:28);
Example 26: (Aib2, A6c7' 26, Nle14)hGIP(l-42)-OH (SEQ ID NO:29);
Example 27: (Aib2, A6c7' 27, Nle14)hGIP(l-42)-OH (SEQ ID NO:30);
Example 28: (Aib2, A6c7'40, Nle14)hGIP(l-42)-OH (SEQ ID NO:31);
Example 29: (Aib2, A6c7'41, Nle'4)hGIP(l-42)-OH (SEQ ID NO:32);
Example 30: (Aib2'28, A6c7, Nle14)hGIP(l-42)-OH (SEQ ID NO:33);
Example 31 : (Aib2, A6c7, Nle14)hGIP(l-30)-NH2 (SEQ ID NO:34);
Example 32: (Aib2, A5c7, Nle14)hGIP(l -3O)-NH2 (SEQ ID NO:35);
Example 33: (Aib2' ", Nle14)hGIP(l -3O)-NH2 (SEQ ID NO:36);
Example 34: (A5c2' 7, Nle14)hGIP(l -3O)-NH2 (SEQ ID NO:37);
Example 35: (Aib2, A5c7' 14)hGIP(l -3O)-NH2 (SEQ ID NO:38);
Example 36: (A6c2' 7, Nle14)hGIP(l -3O)-NH2 (SEQ ID NO:39);
Example 37: (Aib2, A6c7' ", Nlel4)hGIP(l-42)-OH (SEQ ID NO:40);
Example 38: (Aib2' ", A6c14)hGD?(l-30)-NH2 (SEQ ID NO:41);
Example 39: (Aib2, A6c7' 14)hGIP(l -3O)-NH2 (SEQ ID NO:42);
Example 40: (A5c2, Nlel4)hGIP(l-42)-OH (SEQ ID NO:43);
Example 41 : (Aib2' ", A6c14)hGIP(l-42)-OH (SEQ ID NO:44);
Example 42: (Aib2, A6c14)hGIP(l-42)-OH (SEQ ID NO:45); Example 43 : (Aib2, A6c7)hGIP(l -42)-OH (SEQ ID NO:46);
Example 44: (Aib2, A5c7, A6cM)hGIP(l -42)-OH (SEQ ID NO:47);
Example 45: (Aib2' ", Nle14)hGIP(l-42)-OH (SEQ ID NO:48);
Example 46: (Aib2, A5c")hGIP(l-30)-NH2 (SEQ ID NO:49); Example 47: (Aib2' 13)hGIP(l -3O)-NH2 (SEQ ED NO:50);
Example 48: (Aib2, A5c", A6c14)hGIP(l -3O)-NH2 (SEQ ID NO:51);
Example 49: (Aib2' 13, Nle14)hGIP(l-30)-NH2 (SEQ ID NO:52);
Example 50: (Aib2, A5cπ, NIe 14)hGIP( 1-3 O)-NH2 (SEQ ID NO:53);
Example 51 : (Aib2, A6c7' 14)hGIP(l-42)-OH (SEQ ID NO:54); Example 52: (Aib2, A6c7)hGIP(l -3O)-NH2 (SEQ ID NO:55);
Example 53: (Aib2, A5c")hGIP(l-42)-OH (SEQ ID NO:56);
Example 54: (Aib2, A5c", Nle14)hGIP(l-42)-OH (SEQ ID NO:57);
Example 55: (Aib2, A6c7, Nle14)hGIP(l-42)-OH (SEQ ID NO:58);
Example 56: (A5c2' \ A6c14)hGIP(l-42)-OH (SEQ ID NO:59); Example 57: (Aib2> 13, Nle14)hGIP(l-42)-OH (SEQ ID NO:60);
Example 58: (Aib2, A5c7, Nle14)hGIP(l-42)-OH (SEQ ID NO:61);
Example 59: (Aib2, A5c7> 14)hGIP(l-42)-OH (SEQ ID NO:62);
Example 60 : (Aib2' ' 3)hGIP( 1 -42)-OH (SEQ ID NO : 63);
Example 61 : (Aib2, A5c", A6c14)hGIP(l-42)-OH (SEQ ID NO:64); Example 62: (Pro3, Aib13, Nle14)hGIP(l-42)-OH (SEQ ID NO:65);
Example 63: (hPro3, Aib13, Nle14)hGIP(l-42)-OH (SEQ ID NO:66);
Example 64: (Dhp3, Aib13, Nle14)hGIP(l-42)-OH (SEQ ID NO:67);
Example 65: (hPro3, Aib13)hGIP(l-42)-OH (SEQ ID NO:68);
Example 66: (Tic3, Aib13)hGIP(l-42)-OH (SEQ ID NO:69); Example 67: (4Hyp3, Aib13)hGIP(l-42)-OH (SEQ ID NO:70);
Example 68: (4Hyp3, Aib13, Nle14)hGIP(l-42)-OH (SEQ ID NO:71);
Example 69: (Tic3, Aib13, Nle14)hGIP(l-42)-OH (SEQ ID NO:72);
Example 70: (3Hyp3, Aib13, Nle14)hGIP(l-42)-OH (SEQ ID NO:73);
Example 71 : (Tic3, A6c'4)hGIP(l-42)-OH (SEQ ID NO:74); Example 72: (hPro3, A6c14)hGIP(l-42)-OH (SEQ ID NO:75);
Example 73: [Aib2, A6c7, Cys(Psu)41]hGIP(l-42)-OH (SEQ ID NO:76);
Example 74: (hPro3, A5c")hGIP(l-42)-OH (SEQ ID NO:77);
Example 75: (Pro3, Aib13)hGIP(l-42)-OH (SEQ ID NO:78);
Example 76: (Pro3, A5c7' 14)hGIP(l-42)-OH (SEQ ID NO:79); Example 77: (Pro3, A5c")hGIP(l-42)-OH (SEQ ID NO:80);
Example 78: [Aib2, A6c7, Cys(Psu)40]hGIP(l-42)-OH (SEQ ID NO:81);
Example 79: [Aib2, A6c7, Cys(Psu)39]hGIP(l-42)-OH (SEQ ID NO:82); Example 80: [Aib2, A6c7, Cys(Psu)38]hGIP(l-42)-OH (SEQ ID NO:83);
Example 81 : [Aib2, A6c7, Cys(Psu)36]hGIP(l-42)-OH (SEQ ED NO: 84);
Example 82: (Tic3, A5c")hGIP(l-42)-OH (SEQ ID NO:85);
Example 83: (hPro3, A5cu, A6c14)hGIP(l-42)-OH (SEQ ED NO:86); Example 84: (4Hyp3, A6c14)hGEP(l-42)-OH (SEQ ED NO:87);
Example 85: [Aib2, A6c7, Cys(Psu)35]hGEP(l-42)-OH (SEQ ED NO:88);
Example 86: [Aib2, A6c7, Cys(Psu)34]hGEP(l-42)-OH (SEQ ED NO: 89);
Example 87: (4Hyp3, A5cu)hGEP(l-42)-OH (SEQ ED NO:90);
Example 88: (4Hyp3, A5cu, A6c14)hGEP(l-42)-OH (SEQ ED NO:91); Example 89: (Tic3, A5cπ, A6c14)hGEP(l-42)-OH (SEQ ED NO:92);
Example 90: [Aib2, A6c7, Cys(Psu)31]hGEP(l-42)-OH (SEQ ED NO:93);
Example 91 : (Pro3, A6c14)hGEP(l-42)-OH (SEQ ED NO:94);
Example 92: (Pro3, A5cu, Nlel4)hGEP(l -3O)-OH (SEQ ED NO:95);
Example 93: (Aib2, A6c7, Gln43)hGEP(l-43)-OH (SEQ ED NO:96); Example 94: [Aib2, A6c7, Cys(Psu)32]hGEP(l-42)-OH (SEQ ED NO:97);
Example 95: [Aib2, A6c7, Cys(Psu)43]hGEP(l-43)-OH (SEQ ED NO:98);
Example 96: (Pro3, A5cπ, A6c14)hGEP(l -3O)-NH2 (SEQ ED NO:99);
Example 97: (Pro3, A6c7)hGEP(l -3O)-NH2 (SEQ ED NO:100);
Example 98: (Pro3, A5cu)hGEP(l-30)-NH2 (SEQ ID NO: 101); Example 99: [Aib2, A6c7, Cys(Psu)33]hGEP(l-42)-OH (SEQ ED NO: 102);
Example 100: [Aib2, A6c7, Cys(Psu)37]hGEP(l-42)-OH (SEQ ED NO: 103);
Example 101 : (4Hppa', Aib13)hGEP(l-42)-OH (SEQ ED NO: 104);
Example 102: (Pro3, A5cπ, A6cl4)hGEP(l-42)-OH (SEQ ED NO: 105);
Example 103: [Orn1(N-C(O)-(CH2)12-CH3), A6c7]hGEP(l-42)-OH (SEQ ED NO: 106); Example 104: (D-AIa2, A5c1 M0)hGIP(l-42)-OH;
Example 105: (D-AIa2, A5c", His43)hGEP(l-43)-OH;
Example 106: (D-AIa2, A5c1 M1)hGEP(l-42)-OH;
Example 107: (D-AIa2, A6c"' 14> 41)hGIP(l-42)-OH;
Example 108: (Aib2> 13, Pro3, Nle14)hGEP(l -3O)-NH2 (SEQ ED NO: 107); Example 109: (Aib2, Pro3, A6c7)hGEP( 1-3 O)-NH2 (SEQ ED NO: 108);
Example 110: (Aib2, Pro3, A5cn)hGEP(l-30)-NH2 (SEQ ED NO: 109);
Example 111 : (Aib2, Pro3, A5c", Nle14)hGEP(l -3O)-NH2 (SEQ ED NO: 1 10);
Example 112: (Aib2, Pro3, A5cπ, A6c14)hGEP(l -3O)-NH2 (SEQ ED NO: 111);
Example 113: (NMe-Tyr1, Aib2, A5cu, Nle14)hGIP(l-42)-OH (SEQ ED NO: 112); Example 114: (GIy2, A6c11 14 41)hGEP(l-42)-OH (SEQ ED NO: 113);
Example 115: (GIy2, Aib13, A5c40)hGEP(l-42)-OH (SEQ ED NO: 114);
Example 116: (GIy2, A5c"l 41)hGEP(l-42)-OH (SEQ ED NO: 115); Example 117: (GIy2, A5cu, His43)hGIP(l-43)-OH (SEQ ID NO: 116);
Example 118. (GIy2, A5c", Nle14, His43)hGIP(l-43)-OH (SEQ ID NO: 117);
Example 119: (D-AIa2, A5cn, NIe14, His43)hGIP(l-43)-OH;
Example 120: (D-AIa2, A5cπ' M, His43)hGIP(l-43)-OH; Example 121 : (D-AIa2, A5c"' 14)hGIP(l-30)-NH2;
Example 122: (D-AIa2, A5cπ, His31)hGIP(l-31)-NH2; and
Example 123: (Aib2, A5cn' 14, His43)hGIP(l-43)-OH (SEQ ID NO:118).
According to another aspect of the present invention, a compound according to the present invention as summarized hereinabove and claimed in the appended claims may further compose a covalently linked PEG moiety, in which said PEG moiety is covalently linked to the compound via a Cys(maleimide), hCys(maleimide), or Pen(maleimide) linker, to form Cys(succmimide-N-PEG), hCys(succmimide-N-PEG), or Pen(succinimide-N-PEG), wherein "succmimide-N-PEG" is either linear or branched as defined hereinbelow. Such PEG moiety has average molecular weight of from about 2,000 to about 80,000, and preferably such PEG moiety is selected from the group consisting of 5K PEG, 1OK PEG, 2OK PEG, 30K PEG, 40K PEG, 50K PEG, and 6OK PEG, to form
Cys(succimmide-N-5K PEG), Cys(succimmide-N-10K PEG), Cys(succmimide-N-20K PEG), Cys(succimmide-N-30K PEG), Cys(succmimide-N-40K PEG), Cys(succinimide-N-50K PEG), Cys(succinimide-N-60K PEG), hCys(succinimide-N-5K PEG), hCys(succmimide-N-10K PEG), hCys(succmimide-N-20K PEG), hCys(succmimide-N-30K PEG), hCys(succinimide-N-40K PEG), hCys(succinimide-N-50K PEG), hCys(sucαnimide-N-60K PEG), Pen(succmimide-N-5K PEG), Pen(succmimide-N-10K PEG), Pen(succinimide-N-20K PEG), Pen(succimmide-N-30K PEG), Pen(succmimide-N-40K PEG), Pen(succimmide-N-50K PEG), or Pen(succinimide-N-60K PEG).
PEGylation occurs at any one of amino acid residue positions 16, 30, and 31-43, and preferably at any one of amino acid residue positions 32, 33 and 43, whereby Cys(succimmide-N- PEG), hCys(succinimide-N-PEG), or Pen(succinimide-N-PEG) is placed in any one of such amino acid residue positions.
Further, the above formula (I) may be expanded to provide PEGylation sites at positions A44- A47. The C-terminus of such PEGylated compounds of the present invention may be amidated, e g , (Aib2> ") hGEP(l-42)-NH2 (SEQ ID NO: 119), or it may remain as free acid, e g , (Aib2' 11JhGIP(I -42)- OH (SEQ ID NO:4).
DETAILED DESCRIPTION OF THE INVENTION The application employs the following commonly understood abbreviations:
Abu: α-aminobutyπc acid Ace: 1 -amino- 1 -cyclo(C3-C9)alkyl carboxyhc acid
A3c: 1 -amino- 1 -cyclopropanecarboxyhc acid A4c: 1 -amino- 1 -cyclobutanecarboxylic acid
A5c: 1 -amino- 1 -cyclopentanecarboxylic acid
A6c: 1 -amino- 1 -cyclohexanecarboxylic acid
Act: 4-amino-4-carboxytetrahydropyran
Ado: 12-aminododecanoic acid
Aib: α-aminoisobutyric acid
Aic: 2-aminoindan-2-carboxylic acid
Ala or A: alanine β-Ala: beta-alanine
Amp: 4-amino-phenylalanine;
Ape: 4-amino-4-carboxypiperidine :
Arg or R: arginine hArg: homoarginine
Asn or N: asparagine
Asp or D: aspartic acid
Aun: 11 -aminoundecanoic acid
Ava: 5-aminovaleric acid
Cha: β-cyclohexylalanine
Cys or C: cysteine
Dhp: 3 ,4-dehydroproline
Dmt: 5,5-dimethylthiazolidine-4-carboxylic acid
Gaba: γ-aminobutyric acid
GIn or Q: glutamine
GIu or E: glutamic acid
GIy or G: glycine
His or H: histidine
4Hppa: 3-(4-hydroxyphenyl)propionic acid
3Hyp: 3-hydroxyproline
4Hyp: 4-hydroxyproline hPro: homoproline
He or I: isoleucine
4Ktp: 4-ketoproline
Leu or L: leucine
Ly s or K: lysine
Met or M: methionine
NIe: norleucine NMe-Tyr: N-methyl-tyrosine
INaI or 1 -NaI: β-(l -naphthyl)alanine
2NaI or 2-Nal: β-(2-naphthyl)alanine
NIe: norleucine
Nva: norvaline
Orn: ornithine
2PaI or 2-Pal: β-(2-pyridinyl)alanine
3PaI or 3 -Pal: β-(3 -pyridinyl)alanine
4PaI or 4-Pal: β-(4-pyridinyl)alanine
Pen: penicillamine
Phe or F: phenylalanine
(3,4,5F)Phe: 3 ,4,5 -trifluorophenylalanine
(2,3,4,5,6)Phe: 2,3,4,5,6-pentafluorophenylalanine
Pro or P: proline
Psu: N-propylsuccinimide
Ser or S: serine
Taz: β-(4-thiazolyl)alanine
3Thi: β-(3-thienyl)alanine
Thr or T: threonine
Thz: thioproline
Tic: tetrahydroisoquinoline-3-carboxylic acid
Tie: tert-leucine
Tip or W: tryptophan
Tyr or Y: tyrosine
VaI or V: valine other abbreviations used herein are defined as follows:
Acn: acetonitrile
Boc: tert-butyloxycarbonyl
BSA: bovine serum albumin
DCM: dichloromethane
DIPEA: diisopropylethyl amine
DMF: dimethylformamide
ESI: electrospray ionization
Fmoc: 9-fluorenylmethyloxycarbonyl
HBTU: 2-(lH-benzotriazole-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate
HOBt: 1 -hydroxy-benzotriazole HPLC: high performance liquid chromatography
IBMX: isobutylmethylxan thine
LC-MS: liquid chromatography-mass spectrometry
Mtt: methyltrityl
NMP: N-methylpyrrolidone
5K PEG: polyethylene glycol, which may include other functional groups or moieties such as a linker, and which is either linear or branched as defined hereinbelow, with an average total molecular weight of about 5,000
1OK PEG: polyethylene glycol, which may include other functional groups or moieties such as a linker, and which is either linear or branched as defined hereinbelow, with an average total molecular weight of about 10,000
20K PEG: polyethylene glycol, which may include other functional groups or moieties such as a linker, and which is either linear or branched as defined hereinbelow, with an average total molecular weight of about 20,000 30K PEG: polyethylene glycol, which may include other functional groups or moieties such as a linker, and which is either linear or branched as defined hereinbelow, with an average total molecular weight of about 30,000
40K PEG: polyethylene glycol, which may include other functional groups or moieties such as a linker, and which is either linear or branched as defined hereinbelow, with an average total molecular weight of about 40,000
50K PEG: polyethylene glycol, which may include other functional groups or moieties such as a linker, and which is either linear or branched as defined hereinbelow, with an average total molecular weight of about 50,000
6OK PEG: polyethylene glycol, which may include other functional groups or moieties such as a linker, and which is either linear or branched as defined hereinbelow, with an average total molecular weight of about 60,000 tBu: tert-buty\
TIS: triisopropylsilane
Trt: trityl
TFA: trifluoro acetic acid
Z: benzyloxycarbonyl "Cys(succinimide-N-alkyl)" has the structure of:
Figure imgf000017_0001
H
"Cys(Psu)" has the structure of:
"Orn(N-C(O)-(CH2)12-CH3)" has t
Figure imgf000017_0002
he structure of: H O
"Cys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3)" has the structure of:
wherein, x = 1-30, and y = 1-30. "hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3)" has the structure of:
Figure imgf000018_0001
wherein, x = 1-30, and y = 1-30. (O)-NH-(CH2)y-CH3)" has the structure of:
Figure imgf000018_0002
wherein, x = 1-30, and y = 1-30.
"Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3)" has the structure of:
Figure imgf000018_0003
wherein, s = 1-30, and t = 1-30.
"hCys(succinimide-N-(CH2)s-NH-C(O)-(CH2)rCH3)" has the structure of:
Figure imgf000018_0004
wherein s = 1-30, and t = 1-30. "Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)rCH3)" has the structure of:
Figure imgf000019_0001
wherein s = 1-30, and t = 1-30.
Figure imgf000019_0002
'hCys(succinimide-N-PEG)" has the structure of:
"Pen(succinimide-N-PEG)" has the structure of:
Figure imgf000019_0003
"Cys(succinimide-N-(CH2)2-C(O)NH-(CH2)3-PEG)" has the structure of:
Figure imgf000020_0001
"Cys(succinimide-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(PEG)-CH2-PEG)" has the structure of:
Figure imgf000020_0002
With the exception of the N-terminal amino acid, all abbreviations (e.g., Ala) of amino acids in this disclosure stand for the structure of -NH-C(R)(R')-CO-, wherein R and R' each is, independently, hydrogen or the side chain of an amino acid (e.g., R = CH3 and R' = H for Ala), or R and R' may be joined to form a ring system. For the N-terminal amino acid, the abbreviation stands for the structure of (R2R3)N-C(R)(R')-CO-, wherein R2 and R3 are as defined in the above formula (I).
The term "(Ci-C30)hydrocarbon moiety" encompasses alkyl, alkenyl and alkynyl, and in the case of alkenyl and alkynyl there are C2-C30.
A peptide of this invention is also denoted herein by another format, e.g., (A5c2)hGIP(l-42)- OH (SEQ ID NO:3), with the substituted amino acids from the natural sequence placed between the brackets (e.g., A5c2 for Ala2 in hGIP). The numbers between the parentheses refer to the number of amino acids present in the peptide (e.g., hGIP(l-42)-OH (SEQ ID NO: 1) is amino acids 1 through 42 of the peptide sequence for hGIP). The designation "NH2" in hGIP(l -3O)-NH2 (SEQ ID NO:2) indicates that the C-terminus of the peptide is amidated; hGIP(l-42) (SEQ ID NO: 1) or hGIP(l-42)- OH (SEQ ID NO: 1) means that the C-terminus is the free acid.
Human GIP ("hGIP") has the amino acid sequence of:
Tyr-Ala-Glu-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys-Ile-His-Gln-Gln-Asp-Phe-Val- 1 5 10 15 20
Asn-Tφ-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Tφ-Lys-His-Asn-He-Thr-Gln. (SEQ ID NO: 1) 25 30 35 40
"Acyl" refers to R"-C(O)-, where R" is H, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, aryl, alkylaryl, or substituted alkylaryl. "Alkyl" refers to a hydrocarbon group containing one or more carbon atoms, where multiple carbon atoms if present are joined by single bonds. The alkyl hydrocarbon group may be straight- chain or contain one or more branches or cyclic groups.
"Substituted alkyl" refers to an alkyl wherein one or more hydrogen atoms of the hydrocarbon group are replaced with one or more substituents selected from the group consisting of halogen, (i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN, -SH, -NH2, -NHCH3, -NO2, -Ci-20 alkyl substituted with halogens, -CF3, -OCH3, -OCF3, and -(CH2)0-20-COOH. In different embodiments 1, 2, 3 or 4 substituents are present. The presence of -(CH2V20-COOH results in the production of an alkyl acid. Examples of alkyl acids containing, or consisting of, -(CH2)0-20-COOH include 2-norbornane acetic acid, tert-butyτic acid and 3-cyclopentyl propionic acid. "Heteroalkyl" refers to an alkyl wherein one of more of the carbon atoms in the hydrocarbon group are replaced with one or more of the following groups: amino, amido, -O-, -S- or carbonyl. In different embodiments 1 or 2 heteroatoms are present.
"Substituted heteroalkyl" refers to a heteroalkyl wherein one or more hydrogen atoms of the hydrocarbon group are replaced with one or more substituents selected from the group consisting of halogen, -OH, -CN, -SH, -NH2, -NHCH3, -NO2, -C1-20 alkyl substituted with halogens, -CF3, -OCH3, -OCF3, and -(CH2)0-20-COOH. In different embodiments 1, 2, 3 or 4 substituents are present.
"Alkenyl" refers to a hydrocarbon group made up of two or more carbons wherein one or more carbon-carbon double bonds are present. The alkenyl hydrocarbon group may be straight-chain or contain one or more branches or cyclic groups.
"Substituted alkenyl" refers to an alkenyl wherein one or more hydrogens are replaced with one or more substituents selected from the group consisting of halogen, -OH, -CN, -SH, -NH2, -NHCH3, -NO2, -C1-20 alkyl substituted with halogens, -CF3, -OCH3, -OCF3, and -(CH2V20-COOH. In different embodiments 1, 2, 3 or 4 substituents are present. "Aryl" refers to an optionally substituted aromatic group with at least one ring having a conjugated pi-electron system, containing up to three conjugated or fused ring systems. Aryl includes carbocyclic aryl, heterocyclic aryl and biaryl groups. Preferably, the aryl is a 5 or 6 membered ring. Preferred atoms for a heterocyclic aryl are one or more sulfur, oxygen, and/or nitrogen. Examples of aryl include phenyl, 1-naphthyl, 2-naphthyl, indole, quinoline, 2-imidazole, and 9-anthracene. Aryl substituents are selected from the group consisting of -Ci-2O alkyl, -Ci-2O alkoxy, halogen, -OH, -CN, -SH, -NH2, -NO2, -C,.2O alkyl substituted with halogens, -CF3, -OCF3, and -(CH2)O-2O-COOH. In different embodiments the aryl contains 0, 1,2, 3, or 4 substituents.
"Alkylaryl" refers to an "alkyl" joined to an "aryl".
Synthesis
The peptides of this invention can be prepared by standard solid phase peptide synthesis. See, e.g., Stewart, J. M., et al, 1984, Solid Phase Synthesis, Pierce Chemical Co., 2d ed. If R1 is NH-X2- CH2-CONH2, i.e., Z0 = CONH2, the synthesis of the peptide starts with Fmoc-HN-X2-CH2- CONH2 which is coupled to Rink amide MBHA resin. If R1 is NH-X2-CH2-COOH, i. e., Z° = COOH, the synthesis of the peptide starts with Fmoc-HN-X2 -CH2-COOH which is coupled to Wang resin. For this particular step, 2 molar equivalents of Fmoc-HN-X2-COOH, HBTU and HOBt and 10 molar equivalents of DIPEA are used. The coupling time is about 8 hours.
In the synthesis of a GIP analogue of this invention containing A5c, A6c, and/or Aib, the coupling time is 2 hrs for these residues and the residue immediately following them.
The substituents R2 and R3 of the above generic formula can be attached to the free amine of the N-terminal amino acid A1 by standard methods known in the art. For example, alkyl groups, e.g., (Ci-C30)alkyl, can be attached using reductive alkylation. Hydroxyalkyl groups, e.g., (Cr C30)hydroxyalkyl, can also be attached using reductive alkylation wherein the free hydroxy group is protected with a /ert-butyl ester. Acyl groups, e.g., -C(O)X3, can be attached by coupling the free acid, e.g. , -X3COOH, to the free amine of the N-terminal amino acid by mixing the completed resin with 3 molar equivalents of both the free acid and diisopropylcarbodiimide in methylene chloride for about one hour. If the free acid contains a free hydroxy group, e.g., 3-fluoro-4-hydroxyphenylacetic acid, then the coupling should be performed with an additional 3 molar equivalents of HOBT. The following examples describe synthetic methods for making a peptide of this invention, which methods are well-known to those skilled in the art. Other methods are also known to those skilled in the art. The examples are provided for the purpose of illustration and are not meant to limit the scope of the present invention in any manner. Example 73: TAib2. A6c7. Cvs(Psu)4'lhGIPq-42VOH
Solid-phase peptide synthesis was used to assemble the peptide using microwave-assisted Fmoc Chemistry on a Liberty Peptide Synthesizer (CEM; Matthews, NC, USA) at the 0.1 mmole scale. Pre-loaded Fmoc-Gln(Trt)-Wang resin (0.59 mmole/g; Novabiochem, San Diego, CA, USA) was used to generate the C-terminal acid peptide. The resin (0.17 g) was placed in a 50 ml conical tube along with 15 ml of dimethylformamide (DMF) and loaded onto a resin position on the synthesizer. The resin was then quantitatively transferred to the reaction vessel via the automated process. The standard Liberty synthesis protocol for 0.1 mmole scale synthesis was used. This protocol involved deprotectmg the N-termmal Fmoc moiety via an initial treatment with 7 ml of 20% pipeπdme, containing 0.1M N-hydroxybenzotπazole (HOBT), in DMF. The initial deprotection step was for 30 seconds with microwave power (45 watts, maximum temperature of 75 0C), and nitrogen bubbling (3 seconds on / 7 seconds off). The reaction vessel was then drained and a second pipeπdine treatment, identical to the first treatment, except that it was for a 3 -minute duration. The resm was then drained and thoroughly washed with DMF several times. The protected ammo acid, Fmoc- Thr(tBu)-OH, prepared as 0.2M stock solution in DMF, was then added (2.5 ml, 5 eq.), followed by 1.0 ml of 0.45M (4.5 eq.) HBTU [2-(lH-benzo-tπazole-l-yl)-l,l,3,3-tetramethyluromum hexafluorophosaphate] in DMF. This was followed by the addition of 0.5 ml of 2M (10 eq.) DIPEA (dnsopropylethylamme) in NMP (N-methylpyrrollidmone). The coupling step was performed for 5 minutes using 20 watts of microwave power, a max temperature of 75 0C, and the same rate of nitrogen bubbling.
Following the initial coupling step, the reaction vessel was drained to waste and the coupling step repeated. Cycle 2 was then initiated similar to cycle 1. All ammo acids were introduced similarly and a double-coupling strategy was employed throughout the entire sequence. Cycles 1-3, 19-20, 25-26, and 30-39 contained a capping procedure immediately following the coupling step. Capping was performed by adding 7 ml of 0.5M acetic anhydride, containing 0.015M HOBT in NMP, along with 2 ml of the 2M DIPEA solution using a multi-step microwave protocol: 50 watts of power for 30 seconds (65 0C max temperature), followed by 30 seconds of microwave power off, followed by a second round of 30 seconds of microwave power on (50 watts), and then again 30 seconds of no microwave power. The resin was then drained and thoroughly washed with DMF. The following ammo acids (Advanced Chemtech, Louisville, KY, USA) were used: Cycle 1: Fmoc-Cys(Trt)-OH; Cycle 2: Fmoc-Ile-OH; Cycle 3: Fmoc-Asn(Trt)-OH; Cycle 4: Fmoc-His(Trt)-OH; Cycle 5: Fmoc- Lys(Boc)-OH; Cycle 6: Fmoc-Trp(Boc)-OH; Cycle 7: Fmoc-Asp(OtBu)-OH; Cycle 8: Fmoc- Asn(Trt)-OH; Cycle 9: Fmoc-Lys(Boc)-OH; Cycle 10: Fmoc-Lys(Boc)-OH; Cycle 11 : Fmoc-Gly-OH; Cycle 12: Fmoc-Lys(Boc)-OH; Cycle 13: Fmoc-Gln(Trt)-OH; Cycle 14: Fmoc-Ala-OH; Cycle 15: Fmoc-Leu-OH; Cycle 16: Fmoc-Leu-OH; Cycle 17: Fmoc-Trp(Boc)-OH; Cycle 18: Fmoc-Asn(Trt)- OH; Cycle 19: Fmoc-Val-OH; Cycle 20: Fmoc-Phe-OH; Cycle 21 : Fmoc-Asp(OtBu)-OH; Cycle 22: Fmoc-Gln(Trt)-OH; Cycle 23: Fmoc-Gln(Trt)-OH; Cycle 24: Fmoc-His(Trt)-OH; Cycle 25: Fmoc- He-OH; Cycle 26: Fmoc-Lys(Boc)-OH; Cycle 27: Fmoc-Asp(OtBu)-OH; Cycle 28: Fmoc-Met-OH; Cycle 29: Fmoc-Ala-OH; Cycle 30: Fmoc-Ile-OH; Cycle 31: Fmoc-Tyr(tBu)-Ser(psiMe,Me,Pro)-OH; Cycle 32: Fmoc-Asp(OtBu)-OH; Cycle 33: Fmoc-Ser(tBu)-OH; Cycle 34: Fmoc-A6c-OH; Cycle 35: Fmoc-Phe-OH; Cycle 36: Fmoc-Gly-Thr(psiMe,Me,Pro)-OH; Cycle 37: Fmoc-Glu(OtBu)-OH; Cycle 38: Fmoc-Ala-OH; and Cycle 39: Fmoc-Tyr(tBu)-OH. The coupling protocol for Fmoc-His(Trt)-OH was a slightly modified version of the standard protocol. The microwave power was off for the first 2 minutes, followed by 4 minutes with microwave power on (20 watts; max temperature of 50 0C). Once the peptide backbone was complete, standard piperidine treatment was used to remove the N- terminal Fmoc group. The resin was then thoroughly washed with DMF and then transferred back to the 50 ml conical tube using DMF as the transfer solvent.
The resin was deprotected and cleaved from the resin via treatment with 5 ml of the following reagent: 5% TIS, 2% water, 5% (w/v) dithiothrieitol (DTT), 88% TFA, and allowed to mix for 3.5 hours. The filtrate was collected into 45 ml of cold anhydrous ethyl ether. The precipitate was pelleted for 10 minutes at 3500 RPM in a refrigerated centrifuge. The ether was decanted, and the peptide re-suspended in fresh ether. The ether workup was performed a total of 2 times. Following the last ether wash, the peptide was allowed to air dry to remove residual ether. The peptide pellet was resuspended in 8 ml of acetonitrile (Acn) followed by 8 ml of de-ionized water, and allowed to fully dissolve. The peptide solution was then analyzed by mass spectrometry. Mass analysis employing electrospray ionization identified a main product containing a mass of 5011.7 Daltons; corresponding to the desired linear product. The crude product (approximately 500 mg) was analysed by HPLC, employing a 250 x 4.6 mm Cl 8 column (Phenomenex; Torrance, CA, USA) using a gradient of 2-80% acetonitrile (0.1% TFA) over 30 minutes. Analytical HPLC identified a product with 34% purity. The crude peptide was then purified on a preparative HPLC equipped with a Cl 8 reverse phase column using a 10-60% acetonirile (0.1% TFA) over 50 minutes at a 10 ml/min flowrate. The purified peptide was then lyophilized yielding 15 mg of peptide. The linear peptide was then derivatized with N-propylmaleimide (Pma) to generate the propylsuccinimide (Psu) derivative on the Cysteine side chain. The purified linear peptide was brought up in water, adjusted to pH 6.5 with ammonium carbonate, at 5 mg/ml. Five equivalents of Pma was added with constant stirring for 30 seconds. The derivatized peptide solution was then analyzed by mass spectrometry. Mass analysis employing electrospray ionization identified a main product containing a mass of 5150.7 Daltons; corresponding to the desired Psu derivatized product. The product was then re- purified via preparative HPLC using a similar gradient as before. The purified product was analyzed by HPLC for purity (95.10%) and mass spectrometry (5150.9 Daltons) and subsequently lyophilized. Example 103: rθm' (N-C(OV(CH2) n -CHO. A6c7lhGIPO -42VOH
Solid-phase peptide synthesis was used to assemble the peptide using microwave-assisted Fmoc Chemistry on a Liberty Peptide Synthesizer (CEM; Matthews, NC, USA) at the 0.1 mmole scale. Pre-loaded Fmoc-Gln(Trt)-Wang resin (0.59 mmole/g; Novabiochem, San Diego, CA, USA) was used to generate the C-terminal acid peptide. The resin (0.17 g) was placed in a 50 ml conical tube along with 15 ml of dimethylfbrrnamide (DMF) and loaded onto a resin position on the synthesizer. The resin was then quantitatively transferred to the reaction vessel via the automated process. The standard Liberty synthesis protocol for 0.1 mmole scale synthesis was used. This protocol involves deprotecting the N-terminal Fmoc moiety via an initial treatment with 7 ml of 20% piperidine, containing 0.1M N-hydroxybenzotriazole (HOBT), in DMF. The initial deprotection step was for 30 seconds with microwave power (45 watts, maximum temperature of 75 0C), and nitrogen bubbling (3 seconds on / 7 seconds off). The reaction vessel was then drained and a second piperidine treatment, identical to the first treatment, except that it was for a 3 -minute duration. The resin was then drained and thoroughly washed with DMF several times. The protected amino acid, Fmoc- Thr(tBu)-OH, prepared as 0.2M stock solution in DMF, was then added (2.5 ml, 5 eq.), followed by 1.0 ml of 0.45M (4.5 eq.) HBTU [2-(lH-benzo-triazole-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosaphate] in DMF. This was followed by the addition of 0.5 ml of 2M (10 eq.) DIPEA (diisopropylethylamine) in NMP (N-methylpyrrollidinone). The coupling step was performed for 5 minutes using 20 watts of microwave power, a max temperature of 75 0C, and the same rate of nitrogen bubbling.
Following the initial coupling step the reaction vessel was drained to waste and the coupling step repeated. Cycle 2 was then initiated similar to cycle 1. All amino acids were introduced similarly and a double-coupling strategy was employed throughout the entire sequence. Cycles 1-3, 19-20, 25-26, and 30-39 contained a capping procedure immediately following the coupling step. Capping was performed by adding 7 ml of 0.5M acetic anhydride, containing 0.015M HOBT in NMP, along with 2 ml of the 2M DDPEA solution using a multi-step microwave protocol: 50 watts of power for 30 seconds (65 0C max temperature), followed by 30 seconds of microwave power off, followed by a second round of 30 seconds of microwave power on (50 watts), and then again 30 seconds of no microwave power. The resin was then drained and thoroughly washed with DMF. The following amino acids (Advanced Chemtech, Louisville, KY, USA) were used: Cycle 1 : Fmoc-Thr(tBu)-OH; Cycle 2: FmOC-Be-OH; Cycle 3: Fmoc-Asn(Trt)-OH; Cycle 4: Fmoc-His(Trt)-OH; Cycle 5: Fmoc- Lys(Boc)-OH; Cycle 6: Fmoc-Trp(Boc)-OH; Cycle 7: Fmoc-Orn(Mtt)-OH; Cycle 8: Fmoc-Asn(Trt)- OH; Cycle 9: Fmoc-Lys(Boc)-OH; Cycle 10: Fmoc-Lys(Boc)-OH; Cycle 11 : Fmoc-Gly-OH; Cycle 12: Fmoc-Lys(Boc)-OH; Cycle 13: Fmoc-Gln(Trt)-OH; Cycle 14: Fmoc-Ala-OH; Cycle 15: Fmoc- Leu-OH; Cycle 16: Fmoc-Leu-OH; Cycle 17: Fmoc-Trp(Boc)-OH; Cycle 18: Fmoc-Asn(Trt)-OH; Cycle 19: Fmoc-Val-OH; Cycle 20: Fmoc-Phe-OH; Cycle 21: Fmoc-Asp(OtBu)-OH; Cycle 22: Fmoc-Gln(Trt)-OH; Cycle 23: Fmoc-Gln(Trt)-OH; Cycle 24: Fmoc-His(Trt)-OH; Cycle 25: Fmoc- He-OH; Cycle 26: Fmoc-Lys(Boc)-OH; Cycle 27: Fmoc-Asp(OtBu)-OH; Cycle 28: Fmoc-Met-OH; Cycle 29: Fmoc-Ala-OH; Cycle 30: Fmoc-Ile-OH; Cycle 31 : Fmoc-Tyr(tBu)-Ser(psiMe,Me,Pro)-OH; Cycle 32: Fmoc-Asp(OtBu)-OH; Cycle 33: Fmoc-Ser(tBu)-OH; Cycle 34: Fmoc-A6c-OH; Cycle 35: Fmoc-Phe-OH; Cycle 36: Fmoc-Gly-Thr(psiMe,Me,Pro)-OH; Cycle 37: Fmoc-Glu(OtBu)-OH; Cycle 38: Fmoc-Ala-OH; and Cycle 39: Boc-Tyr(tBu)-OH. The coupling protocol for Fmoc-His(Trt)-OH was a slightly modified version of the standard protocol. The microwave power was off for the first 2 minutes, followed by 4 minutes with microwave power on (20 watts; max temperature of 50 0C). Once the peptide backbone was complete, the resin was treated with 12 ml of 1% trifluoroacetic acid (TFA) / 5% triisopropylsilane (TIS) in dichloromethane (DCM) for 5 minutes and a N2 sparge rate of 5 seconds on and 10 seconds off. The resin was then drained and again treated with the 1% TFA / 5% TIS in DCM solution for 5 minutes. This was performed a total of 7 times to effectively remove the Mtt moiety from the Ornithine side chain. The resin was thoroughly washed with DCM several times, and then treated with the standard piperidine treatment in order to neutralize residual TFA salt on the δN of ornithine. Myristic acid, (CH3-(CH2) I2-COOH; Aldrich, St. Louis, MO, USA) prepared as a 0.2M solution in DMF, was coupled to the ornithine side chain using the standard amino acid coupling protocol. The resin was then thoroughly washed with DMF and then transferred back to the 50 ml conical tube using DMF as the transfer solvent.
The resin was deprotected and cleaved from the resin via treatment with 5 ml of the following reagent: 5% TIS, 2% water, 5% (w/v) dithiothrieitol (DTT), 88% TFA, and allowed to mix for 3.5 hours. The filtrate was collected into 45 ml of cold anhydrous ethyl ether. The precipitate was pelleted for 10 minutes at 3500 RPM in a refrigerated centrifuge. The ether was decanted, and the peptide re-suspended in fresh ether. The ether workup was performed a total of 2 times. Following the last ether wash the peptide was allowed to air dry to remove residual ether. The peptide pellet was resuspended in 8 ml of acetonitrile (Acn) followed by 8 ml of de-ionized water, and allowed to fully dissolve. The peptide solution was then analyzed by mass spectrometry. Mass analysis employing electrospray ionization identified a main product containing a mass of 5205.1 Daltons; corresponding to the desired linear product. The crude product (approximately 500 mg) was analysed by HPLC, employing a 250 x 4.6 mm Cl 8 column (Phenomenex; Torrance, CA, USA) using a gradient of 2- 80% acetonitrile (0.1% TFA) over 30 minutes. Analytical HPLC identified a product with 50% purity. The peptide was then purified on a preparative HPLC equipped with a Cl 8 column using a similar elution gradient. The purified product was re-analyzed by HPLC for purity (96.10%) and mass spectrometry (5204.6 Daltons) and subsequently lyophilized. Following lyophillization, 6.2 mg of purified product was obtained representing a 1.2% yield. The PEGylated GIP compounds disclosed herein can be synthesized substantially according to the procedure described for the synthesis of the compound of Example 15, by using PEG- maleimide as the starting material instead of N-propylmaleimide used in Example 15.
Other peptides of the invention can be prepared by a person of ordinary skill in the art using synthetic procedures analogous to those disclosed in the foregoing examples. Physical data for the compounds exemplified herein are given in Table 1.
TABLE 1
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
Functional Assays
A. In Vitro hGIP Receptor Binding Assay
Membranes for in vitro receptor binding assays were prepared by homogenizing the CHO-Kl clonal cells expressing the human recombinant GIP receptor, with a Brinkman Polytron (setting 6, 15 sec), in ice-cold 5OmM Tris-HCl and then subjected to two centrifugations at 39,000 g for 10 minutes, with a resuspension in fresh buffer in between. For the assay, aliquots of the washed membrane preparations were incubated (100 minutes at 250C with 0.05nM [125I]GIP (approximately 2200 Ci/mmol) in 5OmM Tris-HCl, 0.1 mg/ml bacitracin, and 0.1% BSA. The final assay volume was 0.5 ml. The incubations were terminated by rapid filtration through GF/C filters (pre-soaked in 0.5% polyethylenimine) using a Brandel filtration manifold. Each tube and filter were then washed three times with 5-ml aliquots of ice-cold buffer. Specific binding was defined as the total radioligand bound minus that bound in the presence of 100OnM GIP. In vitro hGIP receptor binding data for the compounds exemplified herein are given in Table 2. B. Human and Rat Plasma Half-Life Assay
GIP peptide (50 μL 1 mg/ml) was added to 450 μL plasma (human or rat), vertexed briefly and incubated at 37 0C. 50 μL was removed at various times, like at 0, 1, 2, 3, 4, 8, 24, 32, 48, 56, 72 hours, mixed with 5 μL formic acid and 150 μL acetonitrile in a microcentrifuge tube, vertexed, and centrifuged for 10 minutes at 1OK rpm. The supernatant was transferred to an injection vial and analyzed by LC-MS. The LC-MS system consisted of an API4000 mass spectrometer with an ESI probe. Positive ion mode and full scan detection were used. HPLC separation was carried out on a Luna 3μ C8 (2), 2 x 30 mm column with a gradient from 90% A to 90% B in 10 minutes at a flow rate of 0.3 ml/min. Buffer A was 1% formic acid in water and buffer B was 1% formic acid acetonitrile. Human and rat plasma half-life data for the compounds exemplified herein are given in Table 2.
TABLE 2
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
In comparison to the data listed in Table 2, the in vitro hGIP receptor binding data, and human and rat plasma half-life data for [Pro3]hGIP(l-42)-OH, a compound disclosed in PCT publication WO 00/58360, were measured under the same experimental conditions as described hereinabove to be 170.8 nM, and 10.8 hours and 0.8 hours, respectively.
C. Determination of cyclic AMP stimulation
1 x 105 CHO-Kl cells expressing the human recombinant GIP receptor or RIN-5F insulinoma cells were seeded overnight into 24-well cell culture plates (Corning Incorporate, Corning, NY, USA). For the assay, the cells were preincubated in 500 μl of Hanks balanced salt solution (Sigma, St. Louis, MO, USA) with 0.55mM IBMX (Sigma, St. Louis, MO, USA) adjusted to pH 7.3 for 10 minutes. GIP or its analogs was then added at a concentration of 100 nM. Following a 30-minute incubation at 370C, the plates were placed on ice and 500 μl of ice-cold absolute ethanol was added to stop the reaction. The contents of the wells were collected, spun at 2,700 g for 20 minutes at 40C to remove cellular debris. The cAMP levels in the supernatants were determined by radioimmunoassay (New England Nuclear, Boston, MA, USA).
D. Determination of in vivo Insulin Secretion in Normal Rats
Male Sprague Dawley rats with a body weight of approximately 275-300 g were used as experimental subjects. The day prior to the treatment, right atrial cannulae were implanted via the jugular vein under chlorohydrate. Each cannula was filled with 100 u/ml heparin saline and tied. The rats were fasted for approximately 18 hours prior to dosing with the compound or the vehicle (saline/0.25% BSA). The day of the experiment, aliquots of compound were thawed, brought to room temperature and vortexed thoroughly. A careful check was made for any sign of compound coming out of solution. 10 minutes prior to compound/glucose injection, a 500 μl blood sample was withdrawn and replaced with an equal volume of heparinized saline (10 u/ml). At time 0, a 500 μl blood sample was withdrawn through the cannula. Next, either the vehicle or the appropriate dose of the compound was injected into the cannula and pushed in with the glucose (1 g/kg) or vehicle solution. Finally, 500 μl of volume of heparinized saline (10 u/ml) was used to push in the remaining glucose through the cannula. Additional 500 μl blood samples were withdrawn at 2.5, 5, 10, and 20- minute post-glucose dosing; each immediately followed by a bolus, iv injection of 500 μl heparinized saline (10 u/ml) through the cannula. The plasma was collected from the blood samples by centrifugation, and stored at -2O0C until assay for insulin content. Numerical values of the total insulin secretion, which show the in vivo effects of the compounds of Examples 105, 106, 118, and 119, are summarized in Table 3.
TABLE i
AUC
Vehicle/Vehicle 20.54
Vehicle/Glucose 4.1 1
Example 105 114.70
Example 106 161.73
Example 118 88.22
Example 119 167.48
Administration
The peptides of this invention can be provided in the form of pharmaceutically acceptable salts. Examples of such salts include, but are not limited to, those formed with organic acids (e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, methanesulfonic, toluenesulfonic, or pamoic acid), inorganic acids (e.g., hydrochloric acid, sulfuric acid, or phosphoric acid), and polymeric acids (e.g., tannic acid, carboxymethyl cellulose, polylactic, polyglycolic, or copolymers of polylactic-glycolic acids). A typical method of making a salt of a peptide of the present invention is well known in the art and can be accomplished by standard methods of salt exchange. Accordingly, the TFA salt of a peptide of the present invention (the TFA salt results from the purification of the peptide by using preparative HPLC, eluting with TFA containing buffer solutions) can be converted into another salt, such as an acetate salt by dissolving the peptide in a small amount of 0.25 N acetic acid aqueous solution. The resulting solution is applied to a semi-prep HPLC column (Zorbax, 300 SB, C-8). The column is eluted with (1) 0.1N ammonium acetate aqueous solution for 0.5 hrs, (2) 0.25N acetic acid aqueous solution for 0.5 hrs, and (3) a linear gradient (20% to 100% of solution B over 30 minutes) at a flow rate of 4 ml/min (solution A is 0.25N acetic acid aqueous solution; solution B is 0.25N acetic acid in acetonitrile/water, 80:20). The fractions containing the peptide are collected and lyophilized to dryness.
The dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained. The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment. In general, an effective dosage for the activities of this invention is in the range of 1 x 10"7 to 200 mg/kg/day, preferably 1 x 10"4 to 100 mg/kg/day, which can be administered as a single dose or divided into multiple doses.
The compounds of this invention can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual, or topical routes of administration, and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch. Such dosage forms can also comprise, as is normal practice, additional substances other than such inert diluents, e.g. , lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
Liquid dosage forms for oral administration include, without limitation, pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, and the like, containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.
Preparations according to this invention for parenteral administration include, without limitation, sterile aqueous or non-aqueous solutions, suspensions, emulsions, and the like. Examples of non-aqueous solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
Compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as coca butter or a suppository wax. Compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.
Further, a compound of this invention can be administered in a sustained release composition such as those described in the following patents and patent applications. U.S. Patent No. 5,672,659 teaches sustained release compositions comprising a bioactive agent and a polyester. U.S. Patent No. 5,595,760 teaches sustained release compositions comprising a bioactive agent in a gelable form. U.S. Patent No. 5,821,221 teaches polymeric sustained release compositions comprising a bioactive agent and chitosan. U.S. Patent No.5,916,883 teaches sustained release compositions comprising a bioactive agent and cyclodextrin. PCT publication WO99/38536 teaches absorbable sustained release compositions of a bioactive agent. PCT publication WO00/04916 teaches a process for making microparticles comprising a therapeutic agent such as a peptide in an oil-in-water process. PCT publication WO00/09166 teaches complexes comprising a therapeutic agent such as a peptide and a phosphorylated polymer. PCT publication WO00/25826 teaches complexes comprising a therapeutic agent such as a peptide and a polymer bearing a non-polymerizable lactone.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Also, all publications, patent applications, patents and other references mentioned herein are hereby incorporated by reference, each in its entirety.

Claims

CLAIMSWhat is claimed is:
1. A compound of formula (I),
(R2R3)-A1-A2-A3-A4-A5-A6-A7-A8-A9-A1O-A"-A12-A13-A14-A15-A16-A17-A18-AI9-A2O-A21-A22- AM-A24-A2^A26-A27-A2^A29-A30-A3I.A32.A3^AM.A3S-A36-A37-A38-A39-A40-A41-A42-A43.R1 ,
(I) wherein: A1 is Tyr, 4Hppa, or HN-CH((CH2)n-N(R4R5))-C(O);
A2 is Ala, Abu, D-Abu, Ace, Aib, β-Ala, D-AIa, Gaba, GIy, Ser, D-Ser, Thr, D-Thr, VaI, or D-VaI;
A3 is GIu, Aib, Asp, NMe-Asp, Dhp, Dmt, GIu, NMe-GIu, 3Hyp, 4Hyp, 4Ktp, Pro, hPro, Thz, or Tic; A4 is GIy, Ace, Aib, or β-Ala;
A5 is Thr, Ace, Aib, or Ser;
A6 is Phe, Ace, Aib, Aic, Cha, INaI, 2NaI, 2-Pal, 3-Pal, 4-Pal, (X4,X5,X6,X7,X8)Phe, or Trp; A7 is He, Abu, Ace, Aib, Ala, Cha, Leu, NIe, Phe, Tie, or VaI; A8 is Ser, Aib, or Thr; A9 is Asp, Aib, or GIu;
A10 is Tyr, Ace, Cha, INaI, 2NaI, 2-Pal, 3-Pal, 4-Pal, Phe, or (X4,X5,X6,X7,X8)Phe; A11 is Ser, Ace, Aib, NIe, or Thr;
A12 is He, Abu, Ace, Aib, Ala, Cha, Leu, NIe, Phe, Tie, or VaI; A13 is Ala, Ace, Aib, y9-Ala, D-AIa, GIy, or Ser; A14 is Met, Abu, Ace, Aib, Ala, Cha, He, Leu, NIe, Phe, Tie, or VaI;
A15 is Asp, Aib, or GIu;
A16 is Lys, Amp, Ape, Arg, hArg, Om, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N- alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)- NH-(CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), hCys(succinimide-N-(CH2)s- NH-C(O)-(CH2)t-CH3), or Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)rCH3); A17 is He, Abu, Ace, Aib, Ala, Cha, Leu, NIe, Phe, Tie, or VaI; A18 is His, Amp, Arg, 2-Pal, 3-Pal, 4-Pal, Phe, or Tyr; A19 is GIn, Aib, or Asn; A20 is GIn, Aib, or Asn;
A21 is Asp, Aib, or GIu; A22 is Phe, Ace, Aib, Aic, Cha, INaI, 2NaI, 2-Pal, 3-Pal, 4-Pal, (X4,X5,X6,X7,X8)Phe, or Trp; A23 is VaI, Abu, Ace, Aib, Ala, Cha, He, Leu, NIe, or Tie;
A24 is Asn, Aib, or GIn;
A25 is Tip, Ace, Aib, INaI, 2NaI, 2-Pal, 3-Pal, 4-Pal, Phe, or (X4,X5,X6,X7,X8)Phe;
A26 is Leu, Ace, Aib, Cha, He, NIe, Phe, (X4,X5,X6,X7,X8)Phe, or Tie; A27 is Leu, Ace, Aib, Cha, He, NIe, Phe, (X4,X5,X6,X7,X8)Phe, or Tie,;
A28 is Ala, Ace, or Aib;
A29 is GIn, Aib, Asn, or deleted;
A30 is Lys, Amp, Ape, Arg, hArg, Orn, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N- alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)- NH-(CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), hCys(succinimide-N-(CH2)s- NH-C(O)-(CH2X-CH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), or deleted;
A31 is GIy, Ace, Aib, β-Ala, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y- CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)rCH3), hCys(succinimide-N-(CH2)s-NH- C(O)-(CH2X-CH3), His, Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), or deleted;
A32 is Lys, Amp, Ape, Arg, hArg, Orn, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N- alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)- NH-(CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2),-CH3), hCys(succinimide-N-(CH2)s- NH-C(O)-(CH2X-CH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)rCH3), or deleted;
A33 is Lys, Amp, Ape, Arg, hArg, Orn, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N- alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)- NH-(CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)rCH3), hCys(succinimide-N-(CH2)s- NH-C(O)-(CH2X-CH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), or deleted;
A34 is Asn, Aib, GIn, Ser, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y- CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), hCys(succinimide-N-(CH2)s-NH- C(O)-(CH2)t-CH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)rCH3), or deleted;
A35 is Asp, Aib, GIu, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y- CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)rCH3), hCys(succinimide-N-(CH2)s-NH- C(O)-(CH2X-CH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2χ-CH3), or deleted; A36 is Trp, Ace, Aib, INaI, 2NaI, 2-Pal, 3-Pal, 4-Pal, Phe, (X4,X5,X6,X7,X8)Phe, HN- CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide- N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), hCys(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Cys(succinimide-N-(CH2)S-NH- C(O)-(CH2)rCH3), hCys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), Pen(succinimide-N-(CH2)S- NH-C(O)-(CH2)t-CH3), or deleted;
A37 is Lys, Amp, Ape, Arg, hArg, Orn, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N- alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3)) Pen(succinimide-N-(CH2)x-C(O)- NH-(CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), hCys(succinimide-N-(CH2)s- NH-C(O)-(CH2)t-CH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), or deleted;
A38 is His, Amp, 2-Pal, 3 -Pal, 4-Pal, Phe, Tyr, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide- N-(CH2)x-C(O)-NH-(CH2)y-CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), hCys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)t- CH3), or deleted;
A39 is Asn, Aib, GIn, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y- CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), hCys(succinimide-N-(CH2)s-NH- C(O)-(CH2)t-CH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), or deleted;
A40 is He, Ace, Aib, Ser, Thr, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y- CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), hCys(succinimide-N-(CH2)s-NH- C(O)-(CH2),-CH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), or deleted;
A41 is Thr, Ace, Aib, Asn, GIn, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y- CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3)> hCys(succinimide-N-(CH2)s-NH- C(O)-(CH2)t-CH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), or deleted;
A42 is GIn, Ace, Aib, Asn, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), PenCsuccinimide-N-alkyl), Cys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y- CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Pen(succinimide-N-(CH2)x-C(O)-NH- (CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), hCys(succinimide-N-(CH2)s-NH- C(O)-(CH2)rCH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)rCH3), or deleted; A43 is Ace, Aib, Ala, Asp, GIn, His, Phe, Thr, Trp, HN-CH((CH2)n-N(R4R5))-C(O), Cys(succinimide-N-alkyl), hCys(succinimide-N-alkyl), Pen(succinimide-N-alkyl), Cys(succinimide- N-(CH2)x-C(O)-NH-(CH2)y-CH3), hCys(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3)J Pen(succinimide-N-(CH2)x-C(O)-NH-(CH2)y-CH3), Cys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), hCys(succinimide-N-(CH2)s-NH-C(O)-(CH2)t-CH3), Pen(succinimide-N-(CH2)s-NH-C(O)-(CH2)t- CH3), or deleted;
R1 is OH, NH2, (CrC30)alkoxy, or NH-X2-CH2-Z°, wherein X2 is a (C0-C30) hydrocarbon moiety and Z0 is H, OH, CO2H, or CONH2; each of R2, R3, R4 and R5 is independently selected from the group consisting of H, (Ci - C30)alkyl, (C,-C30)heteroalkyl, (C,-C30)acyl, (C2-C30)alkenyl, (C2-C30)alkynyl, aryl(C,-C30)alkyl, aryl(CrC30)acyl, substituted (Ci-C30)alkyl, substituted (Ci-C30)heteroalkyl, substituted (Ci-C30)acyl, substituted (C2-C30)alkenyl, substituted (C2-C30)alkynyl, substituted aryl(Ci-C30)alkyl, and substituted aryl(Ci-C30)acyl; provided that when R2 is (CrC30)acyl, aryl(CrC30)acyl, substituted (C1-C30)HCyI, or substituted aryl(C1-C30)acyl, then R3 is H, (CrC30)alkyl, (C,-C30)heteroalkyl, (C2-C30)alkenyl, (C2- C30)alkynyl, aryl(Ci-C30)alkyl, substituted (Ci-C30)alkyl, substituted (C]-C30)heteroalkyl, substituted (C2-C30)alkenyl, substituted (C2-C30)alkynyl, or substituted aryl(Ci-C30)alkyl; further provided that when R4 is (C1-C30)acyl, aryl(Ci-C30)acyl, substituted (C1-C3(OaCyI, or substituted aryl(C]-C3o)acyl, then R5 is H, (C,-C30)alkyl, (C1-C30)heteroalkyl, (C2-C30)alkenyl, (C2-C30)alkynyl, aryl(CrC30)alkyl, substituted (Ci-C30)alkyl, substituted (CrC30)heteroalkyl, substituted (C2-C30)alkenyl, substituted (C2- C30)alkynyl, or substituted aryl(Ci-C30)alkyl; n is, independently for each occurrence, an integer from 1 to 5 inclusive; s, t, x and y each is, independently for each occurrence, an integer from 1 to 30 inclusive;
X4, X5, X6, X7 and X8 each is, independently for each occurrence, H, F, Cl, Br, I, (C1.10)alkyl, substituted (C1-10)alkyl, aryl, substituted aryl, OH, NH2, NO2, or CN; provided that when A1 is 4Hppa, then R2 and R3 are deleted; further provided that only one amino acid at positions 1, 2 and 3 of the compound is substituted or modified; and further provided that a compound of formula (I) is not (D-Ala2)hGIP(l-42), (Pro3)hGIP(l-42) (SEQ ID NO: 120), (Aib3)hGIP(l-42) (SEQ ID NO: 121), (Se^hGIP(I -42) (SEQ ID NO: 122), (Abu2)hGIP(l-42) (SEQ ID NO: 123), (D-Abu2)hGIP(l-42), (D-Ser2)hGIP(l-42), (D-Thr2)hGIP(l-42), or (D-Val2)hGIP(l-42); or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1, wherein: A1 is Tyr, 4Hppa, or Orn(N-C(O)-(CH2)l2-CH3);
A2 is Ala, A5c, A6c, Aib, D-AIa, GIy, or Ser; A3 is GIu, Dhp, 3Hyp, 4Hyp, Pro, hPro, or Tic; A4 is GIy or Aib;
A5 is Thr, A5c, or Aib;
A6 is Phe or A6c;
A7 is He, A5c, A6c, or Aib; A8 is Ser or Aib;
A9 is Asp or Aib;
A10 is Tyr;
A" is Ser, A5c, A6c, Aib, or NIe;
A12 is He, A5c, or Aib; A13 is Ala or Aib;
A14 is Met, A5c, A6c, or NIe;
A15 is Asp;
A16 is Lys;
A17 is He or A6c; A18 is His;
A19 is GIn;
A20 is GIn;
A21 is Asp;
A22 is Phe; A23 is VaI;
A24 is Asn;
A25 is Trp;
A26 is Leu or A6c;
A27 is Leu or A6c; A28 is Ala or Aib;
A29 is GIn;
A30 is Lys;
A31 is GIy, Aib, Cys(Psu), His, or deleted;
A32 is Lys, Cys(Psu), or deleted; A33 is Lys, Cys(Psu), or deleted;
A34 is Asn, Cys(Psu), or deleted;
A35 is Asp, Cys(Psu), or deleted;
A36 is Trp, Cys(Psu), or deleted;
A37 is Lys, Cys(Psu), or deleted; A38 is His, Cys(Psu), or deleted;
A39 is Asn, Cys(Psu), or deleted;
A40 is He, A5c, A6c, Cys(Psu), or deleted; A41 is Thr, A5c, A6c, Aib, Cys(Psu), or deleted; A42 is GIn or deleted; A43 is Cys(Psu), GIn, His, or deleted; and provided that the compound contains at least one additional amino acid substitution or modification at positions 4-43; or a pharmaceutically acceptable salt thereof.
3. A compound according to claim 2, wherein said compound is:
(Aib2' π)hGIP(l-42)-OH (SEQ ID NO:4); (Aib2' 9)hGIP(l-42)-OH (SEQ ID NO:5);
(Aib2' 7)hGIP(l-42)-OH (SEQ ID NO:6);
(Aib2' 5)hGIP(l-42)-OH (SEQ ID NO:7);
(Aib2, A5c5)hGIP(l-42)-OH (SEQ ID NO:8);
(Aib2, A5c7)hGIP(l-42)-OH (SEQ ID NO:9); (Aib2, A5c12)hGIP(l-42)-OH (SEQ ED NO:10);
(Aib2' 12)hGIP(l-42)-OH (SEQ ID NO: 11);
(Aib2' 8)hGIP(l-42)-OH (SEQ ID NO: 12);
(Aib2'4)hGIP(l-42)-OH (SEQ E) NO: 13);
(Aib2, A5c5)hGIP(l -3O)-NH2 (SEQ ID NO: 14); (Aib2, A5c7)hGIP(l -3O)-NH2 (SEQ ID NO: 15);
(Aib2, A5c12)hGIP(l -3O)-NH2 (SEQ ID NO: 16);
(Aib2' 4)hGIP(l -3O)-NH2 (SEQ ID NO: 17);
(Aib2' 5)hGIP(l -3O)-NH2 (SEQ ID NO: 18);
(Aib2' 7)hGIP(l -3O)-NH2 (SEQ ID NO: 19); (Aib2' 8)hGIP(l -3O)-NH2 (SEQ ID NO:20);
(Aib2' 9)hGIP(l-30)-NH2 (SEQ ID NO:21);
(Aib2' ")hGIP(l -3O)-NH2 (SEQ K) NO:22);
(Aib2' 12)hGIP(l -3O)-NH2 (SEQ ID NO:23);
(Aib2' 13, A6c7, Nle14)hGIP(l-42)-OH (SEQ ID NO:24); (Aib2' 31, A6c7)hGIP(l-42)-OH (SEQ ID NO:25);
(Aib2'41, A6c7)hGIP(l-42)-OH (SEQ ID NO:26);
(Aib2' 31, A6c7, NleM)hGIP(l-42)-OH (SEQ ID NO:27);
(Aib2'41, A6c7, Nle14)hGIP(l-42)-OH (SEQ ID NO:28);
(Aib2, A6c7' 26, Nle14)hGIP(l-42)-OH (SEQ YD NO:29); (Aib2, A6c7' 27, Nle14)hGIP(l-42)-OH (SEQ ID NO:30);
(Aib2, A6c7'40, Nle14)hGIP(l-42)-OH (SEQ ID NO:31);
(Aib2, A6c7'41, Nle14)hGIP(l-42)-OH (SEQ ID NO:32); (Aib2' 28, A6c7, Nle'4)hGEP(l-42)-OH (SEQ ID NO:33);
(Aib2, A6c7, Nle14)hGIP(l-30)-NH2 (SEQ ID NO:34);
(Aib2, A5c7, Nle14)hGIP(l -3O)-NH2 (SEQ ID NO:35);
(Aib2' ", Nle14)hGIP(l -3O)-NH2 (SEQ DD NO:36); (A5c2' \ Nle14)hGIP(l -3O)-NH2 (SEQ ID NO:37);
(Aib2, A5c7' 14)hGEP(l -3O)-NH2 (SEQ ID NO:38);
(A6c2> \ Nle14)hGIP(l -3O)-NH2 (SEQ ID NO:39);
(Aib2, A6c7' 17, Nle14)hGIP(l-42)-OH (SEQ ID NO:40);
(Aib2' ", A6c14)hGIP(l-30)-NH2 (SEQ ID NO:41); (Aib2, A6c7' 14)hGIP(l-30)-NH2 (SEQ ID NO:42);
(A5c2, Nle14)hGIP(l-42)-OH (SEQ ID NO:43);
(Aib2> ", A6c14)hGIP(l-42)-OH (SEQ ID NO:44);
(Aib2, A6c14)hGIP(l-42)-OH (SEQ ED NO:45);
(Aib2, A6c7)hGIP(l-42)-OH (SEQ ID NO:46); (Aib2, A5c7, A6c14)hGIP(l-42)-OH (SEQ ID NO:47);
(Aib2' ", Nle14)hGIP(l-42)-OH (SEQ ID NO:48);
(Aib2, A5cπ)hGEP(l -3O)-NH2 (SEQ ID NO:49);
(Aib2 13)hGB?(l-30)-NH2 (SEQ ID NO:50);
(Aib2, A5cu, A6c14)hGC?(l -3O)-NH2 (SEQ ID NO:51); (Aib2> 13, Nle14)hGE?(l -3O)-NH2 (SEQ ID NO:52);
(Aib2, A5cπ, Nle14)hGIP(l -3O)-NH2 (SEQ ID NO:53);
(Aib2, A6c7' 14)hGIP(l-42)-OH (SEQ ID NO:54);
(Aib2, A6c>GIP(l -3O)-NH2 (SEQ ID NO:55);
(Aib2, A5c")hGIP(l-42)-OH (SEQ ID NO:56); (Aib2, A5cπ, Nlel4)hGIP(l-42)-OH (SEQ ID NO:57);
(Aib2, A6c7, Nle14)hGD?(l-42)-OH (SEQ ID NO:58);
(A5c2' 7, A6c'4)hGIP(l-42)-OH (SEQ ID NO:59);
(Aib2' 13, Nle14)hGE?(l-42)-OH (SEQ ID NO:60);
(Aib2, A5c7, Nlel4)hGIP(l-42)-OH (SEQ ID NO:61); (Aib2, A5c7' l4)hGD?(l-42)-OH (SEQ ID NO:62);
(Aib2' 13)hGD?(l-42)-OH (SEQ ID NO:63);
(Aib2, A5c", A6c14)hGE?(l-42)-OH (SEQ ID NO:64);
(Pro3, Aib13, Nle14)hGIP(l-42)-OH (SEQ ED NO:65);
(hPro3, Aib13, NleM)hGEP(l-42)-OH (SEQ ED NO:66); (Dhp3, Aib13, Nle14)hGEP(l-42)-OH (SEQ ED NO:67);
(hPro3, Aib13)hGEP(l-42)-OH (SEQ ED NO:68);
(Tic3, Aib13)hGEP(l-42)-OH (SEQ ED NO:69); (4Hyp3, Aib13)hGIP(l-42)-OH (SEQ ID NO:70);
(4Hyp3, Aib13, Nle14)hGIP(l-42)-OH (SEQ ID NO:71);
(Tic3, Aib13, NleI4)hGEP(l-42)-OH (SEQ ID NO:72);
(3Hyp3, Aib13, Nle14)hGIP(l-42)-OH (SEQ ID NO:73); (Tic3, A6c'4)hGIP(l-42)-OH (SEQ ID NO:74);
(hPro3, A6c14)hGIP(l-42)-OH (SEQ ID NO:75);
[Aib2, A6c7, Cys(Psu)41]hGIP(l-42)-OH (SEQ ID NO:76);
(hPro3, A5C1 ^hGIP(I -42)-OH (SEQ ID NO:77);
(Pro3, Aib13)hGEP(l-42)-OH (SEQ ID NO:78); (Pro3, A5c7' 14)hGIP(l-42)-OH (SEQ ID NO:79);
(Pro3, A5cn)hGIP(l-42)-OH (SEQ ID NO:80);
[Aib2, A6c7, Cys(Psu)40]hGIP(l-42)-OH (SEQ ID NO: 81);
[Aib2, A6c7, Cys(Psu)39]hGIP(l-42)-OH (SEQ ID NO:82);
[Aib2, A6c7, Cys(Psu)38]hGIP(l-42)-OH (SEQ ID NO:83); [Aib2, A6c7, Cys(Psu)36]hGIP( 1 -42)-OH (SEQ ID NO : 84);
(Tic3, A5c")hGIP(l-42)-OH (SEQ ID NO:85);
(hPro3, A5cH, A6c14)hGIP(l-42)-OH (SEQ ID NO:86);
(4Hyp3, A6c14)hGIP(l-42)-OH (SEQ ID NO:87);
[Aib2, A6c7, Cys(Psu)35]hGIP(l-42)-OH (SEQ ID NO: 88); [Aib2, A6c7, Cys(Psu)34]hGIP(l -42)-OH (SEQ ID NO: 89);
(4Hyp3, A5C1 ^hGIP(I -42)-OH (SEQ ID NO:90);
(4Hyp3, A5cu, A6c14)hGIP(l-42)-OH (SEQ ID NO:91);
(Tic3, A5cπ, A6c14)hGIP(l-42)-OH (SEQ ID NO:92);
[Aib2, A6c7, Cys(Psu)31]hGIP(l-42)-OH (SEQ ID NO:93); (Pro3, A6c14)hGIP(l-42)-OH (SEQ ID NO:94);
(Pro3, A5cn, Nle14)hGIP(l -3O)-OH (SEQ ID NO:95);
(Aib2, A6c7, Gln43)hGIP(l-43)-OH (SEQ ID NO:96);
[Aib2, A6c7, Cys(Psu)32]hGIP(l-42)-OH (SEQ ID NO:97);
[Aib2, A6c7, Cys(Psu)43]hGIP(l-43)-OH (SEQ ID NO:98); (Pro3, A5c", A6c'4)hGIP(l -3O)-NH2 (SEQ ID NO:99);
(Pro3, A6c7)hGIP(l -3O)-NH2 (SEQ ID NO: 100);
(Pro3, A5cn)hGIP(l-30)-NH2 (SEQ ID NO: 101);
[Aib2, A6c7, Cys(Psu)33]hGIP(l-42)-OH (SEQ ID NO: 102);
[Aib2, A6c7, Cys(Psu)37]hGIP(l-42)-OH (SEQ ID NO: 103); (4HpPa1, Aib13)hGIP(l-42)-OH (SEQ ID NO:104);
(Pro3, A5cπ, A6c14)hGIP(l-42)-OH (SEQ ID NO: 105);
[Orn'(N-C(O)-(CH2)12-CH3), A6c7]hGIP(l-42)-OH (SEQ ID NO: 106); (D-AIa2, A5c1 M0)hGIP(l-42)-OH;
(D-AIa2, A5cπ, His43)hGIP(l-43)-OH;
(D-AIa2, A5c11 41)hGIP(l-42)-OH;
(D-AIa2, A6cπ- 14'41)hGIP(l-42)-OH; (GIy2, A6cu' 14' 41)hGIP(l-42)-OH (SEQ ID NO: 113);
(GIy2, Aib13, A5c40)hGIP(l-42)-OH (SEQ ID NO: 114);
(GIy2, A5c1 I 41)hGIP(l-42)-OH (SEQ ID NO: 115);
(GIy2, A5cπ, His43)hGIP(l-43)-OH (SEQ ID NO: 116);
(GIy2, A5c", NIe14, His43)hGIP(l-43)-OH (SEQ ID NO: 117); (D-AIa2, A5cu, NIe14, His43)hGIP(l-43)-OH;
(D-AIa2, A5cπ' 14, His43)hGIP(l-43)-OH;
(D-AIa2, A5cπ> 14)hGIP(l-30)-NH2;
(D-AIa2, A5cπ, His31)hGIP(l-31)-NH2; or
(Aib2, A5c11 14, His43)hGIP(l-43)-OH (SEQ ID NO: 118); or a pharmaceutical salt thereof.
4. A compound according to claim 2, wherein A2 is D-AIa, or a pharmaceutically acceptable salt thereof.
5. A compound according to claim 4, wherein said compound is:
(D-AIa2, A5cπ' 40)hGIP(l-42)-OH; (D-AIa2, A5cπ, His43)hGIP(l-43)-OH; (D-AIa2, A5c1 M1)hGIP(l-42)-OH; (D-AIa2, A6cu> 14'41)hGIP(l-42)-OH; (D-AIa2, A5cu, NIe14, His43)hGIP(l-43)-OH;
(D-AIa2, A5c"' M, His43)hGIP(l-43)-OH; (D-AIa2, A5c"' 14)hGIP(l -3O)-NH2; or (D-AIa2, A5cπ, His31)hGIP(l-31)-NH2; or a pharmaceutical salt thereof.
6. A compound according to claim 2, wherein A31 to A43 are deleted, or a pharmaceutically acceptable salt thereof.
7. A compound according to claim 6, wherein said compound is: (Aib2, A5c5)hGIP(l -3O)-NH2 (SEQ ID NO: 14);
(Aib2, A5c7)hGEP(l -3O)-NH2 (SEQ ID NO: 15); (Aib2, A5c12)hGIP(l -3O)-NH2 (SEQ ID NO: 16); (Aib2 4)hGIP(l-30)-NH2 (SEQ ID NO: 17); (Aib2 5)hGEP(l -3O)-NH2 (SEQ ID NO: 18);
(Aib2' 7)hGEP(l -3O)-NH2 (SEQ ID NO: 19);
(Aib2' 8)hGEP( 1-3 O)-NH2 (SEQ ID NO:20);
(Aib2' 9)hGEP(l -3O)-NH2 (SEQ ID NO:21); (Aib2' π)hGLP(l -3O)-NH2 (SEQ ED NO:22);
(Aib2' l2)hGIP(l-30)-NH2 (SEQ ID NO:23);
(Aib2, A6c7, NleM)hGEP(l -3O)-NH2 (SEQ ID NO:34);
(Aib2, A5c7, Nle14)hGIP(l-30)-NH2 (SEQ ID NO:35);
(Aib2> π, Nle14)hGC?(l -3O)-NH2 (SEQ ID NO:36); (A5c2' \ Nle14)hGE?(l -3O)-NH2 (SEQ ID NO:37);
(Aib2, A5c7' 14)hGIP(l -3O)-NH2 (SEQ ID NO:38);
(A6c2' \ Nle14)hGEP(l -3O)-NH2 (SEQ ID NO:39);
(Aib2 11, A6c14)hGC?(l -3O)-NH2 (SEQ ID NO:41);
(Aib2, A6c7' 14)hGB?(l -3O)-NH2 (SEQ ID NO:42); (Aib2, A5cu)hGEP(l -3O)-NH2 (SEQ ID NO:49);
(Aib2' 13)hGIP(l -3O)-NH2 (SEQ ID NO:50);
(Aib2, A5cπ, A6c14)hGD?(l-30)-NH2 (SEQ ID NO:51);
(Aib2' 13, Nle14)hGIP(l-30)-NH2 (SEQ ID NO:52);
(Aib2, A5cπ, Nle14)hGIP(l -3O)-NH2 (SEQ ID NO:53); (Aib2, A6c7)hGEP(l -3O)-NH2 (SEQ LD NO:55);
(Pro3, A5cπ, Nle14)hGIP(l -3O)-OH (SEQ ED NO:95);
(Pro3, A5cπ, A6c14)hGEP(l -3O)-NH2 (SEQ LD NO:99);
(Pro3, A6c7)hGEP(l -3O)-NH2 (SEQ LD NO:100);
(Pro3, A5cπ)hGEP(l-30)-NH2 (SEQ ED NO: 101); or (D-AIa2, A5c11> 14)hGIP(l -3O)-NH2 (SEQ ED NO: 121); or a pharmaceutical salt thereof.
8. A compound consisting essentially of a sequence of the first 30 consecutive amino acid residues from the N-terminal end of the native hGIP amino acid sequence, wherein: the sequence comprises A5c, A6c, Aib, D-AIa, GIy or Ser substitution at position 2, and at least one additional amino acid substitution or modification at positions 3-30; or a pharmaceutically acceptable salt thereof.
9. A compound according to claim 8, wherein: A2 is Aib; A3 is Pro; and at least one of A7, A11, A13 and A14 is not the amino acid residue of the corresponding position in the native GEP; or a pharmaceutically acceptable salt thereof.
10. A compound according to claim 9, wherein said compound is: (Aib2' 13, Pro3, Nle14)hGIP(l-30)-NH2 (SEQ ID NO:107);
(Aib2, Pro3, A6c7)hGIP(l -3O)-NH2 (SEQ ID NO:108); (Aib2, Pro3, A5c")hGIP(l -3O)-NH2 (SEQ ID NO: 109); (Aib2, Pro3, A5cπ, Nle14)hGIP(l -3O)-NH2 (SEQ ID NO: 110); or
(Aib2, Pro3, A5c", A6cM)hGIP(l-30)-NH2 (SEQ DD NO: 111); or a pharmaceutical salt thereof.
11. A GIP analogue comprising A5c, A6c, Aib, D-AIa, GIy or Ser substitution at position 2, and at least one additional amino acid substitution or modification at positions 1 and 3-42; or a pharmaceutically acceptable salt thereof.
12. A compound according to claim 11, wherein the sequence comprises Aib substitution at position 2, or a pharmaceutically acceptable salt thereof.
13. A compound according to claim 12, wherein said compound is:
(NMe-Tyr1, Aib2, A5cu, Nle14)hGIP(l-42)-OH (SEQ ID NO: 112); or a pharmaceutical salt thereof.
14. A compound according to claim 2, wherein: A2 is Ala, A5c, A6c, or GIy; and A3 is
GIu, Dhp, 3Hyp, 4Hyp, hPro, or Tic; or a pharmaceutically acceptable salt thereof.
15. A compound according to claim 14, wherein said compound is: (hPro3, Aib13, Nle14)hGEP(l-42)-OH (SEQ ID NO:66);
(Dhp3, Aib13, Nle14)hGIP(l-42)-OH (SEQ ID NO:67);
(hPro3, Aib13)hGIP(l-42)-OH (SEQ ID NO:68);
(Tic3, Aibl3)hGIP(l-42)-OH (SEQ ID NO:69);
(4Hyp3, Aib13)hGIP(l-42)-OH (SEQ ID NO:70); (4Hyp3, Aib13, Nle14)hGIP(l-42)-OH (SEQ E) NO:71);
(Tic3, Aib13, Nle14)hGIP(l-42)-OH (SEQ ID NO:72);
(3Hyp3, Aib13, Nle14)hGIP(l-42)-OH (SEQ ID NO:73);
(Tic3, A6c14)hGIP(l-42)-OH (SEQ ID NO:74);
(hPro3, A6c14)hGD?(l-42)-OH (SEQ ID NO:75); (hPro3, A5c")hGIP(l-42)-OH (SEQ ID NO:77);
(Tic3, A5c")hGIP(l-42)-OH (SEQ ID NO:85);
(hPro3, A5cu, A6c14)hGIP(l-42)-OH (SEQ ID NO:86);
(4Hyp3, A6c14)hGIP(l-42)-OH (SEQ ID NO:87);
(4Hyp3, A5cπ)hGIP(l-42)-OH (SEQ ID NO:90); (4Hyp3, A5c", A6c14)hGIP(l-42)-OH (SEQ ID NO:91); (Tic3, A5cπ, A6c14)hGIP(l-42)-OH (SEQ ID NO:92); (4Hppa\ Aib13)hGIP(l-42)-OH (SEQ ID NO: 104); [Om'CN-CCOHCHOn-CHs), A6c7]hGIP(l-42)-OH (SEQ ID NO: 106); (GIy2, A6c"' 14-41)hGIP(l-42)-OH (SEQ ID NO: 113);
(GIy2, Aib13, A5c40)hGIP(l-42)-OH (SEQ ID NO: 114); (GIy2, A5c11> 41)hGIP(l-42)-OH (SEQ ID NO: 115); (GIy2, A5cπ, His43)hGIP(l-43)-OH (SEQ ID NO:116); or (GIy2, A5c", NIe14, His43)hGIP(l-43)-OH (SEQ ID NO:117); or a pharmaceutical salt thereof.
16. A compound according to any one of claims 1-15, further comprising a covalently linked PEG moiety, or a pharmaceutically acceptable salt thereof.
17. A compound according to claim 16, wherein said PEG is linked to the compound via a Cys(maleimide), hCys(maleimide), or Pen(maleimide) linker, to form Cys(succinimide-N-PEG), hCys(succinimide-N-PEG), or Pen(succinimide -N-PEG), or a pharmaceutically acceptable salt thereof.
18. A compound according to claim 17, wherein PEGylation occurs at any one of amino acid residue positions 16, 30, and 31-43, whereby Cys(succinimide-N-PEG), hCys(succinimide-N- PEG), or Pen(succinimide-N-PEG) is placed in any one of amino acid residue positions 16, 30, and 31-43, or a pharmaceutically acceptable salt thereof.
19. A compound according to claim 18, wherein PEGylation occurs at any one of amino acid residue positions 32, 33 and 43, whereby Cys(succinimide-N-PEG), hCys(succinimide-N-PEG), or Pen(succinimide-N-PEG) is placed in any one of amino acid residue positions 32, 33 and 43, or a pharmaceutically acceptable salt thereof.
20. A compound according to claim 19, wherein said PEG moiety has average molecular weight of from about 2,000 to about 80,000, or a pharmaceutically acceptable salt thereof.
21. A compound according to claim 20, wherein said PEG is selected from the group consisting of 5K PEG, 1OK PEG, 2OK PEG, 30K PEG, 4OK PEG, 50K PEG, and 6OK PEG, to form Cys(succinimide-N-5K PEG), Cys(succinimide-N-10K PEG), Cys(succinimide-N-20K PEG), Cys(succinimide-N-30K PEG), Cys(succinimide-N-40K PEG), Cys(succinimide-N-50K PEG), Cys(succinimide-N-60K PEG), hCys(succinimide-N-5K PEG), hCys(succinimide-N-10K PEG), hCys(succinimide-N-20K PEG), hCys(succinimide-N-30K PEG), hCys(succinimide-N-40K PEG), hCys(succinimide-N-50K PEG), hCys(succinimide-N-60K PEG), Pen(succinimide-N-5K PEG), Pen(succinimide-N-10K PEG), Pen(succinimide-N-20K PEG), PenCsuccinimide-N-SOK PEG), Pen(succinimide-N-40K PEG), Pen(succinimide-N-50K PEG), or Pen(succinimide-N-60K PEG), or a pharmaceutically acceptable salt thereof.
22. A compound according to any one of claims 17-21, wherein said succinimide-N-PEG is linear, or a pharmaceutically acceptable salt thereof.
23. A compound according to claim 22, wherein said linear succinimide-N-PEG is succinimide-N-(CH2)2-C(O)NH-(CH2)3-PEG, or a pharmaceutically acceptable salt thereof.
24. A compound according to any one of claims 17-21, wherein said succinimide-N-PEG is branched, or a pharmaceutically acceptable salt thereof.
25. A compound according to claim 24, wherein said branched succinimide-N-PEG is succinimide-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH-PEG-CH2-PEG, or a pharmaceutically acceptable salt thereof.
26. A pharmaceutical composition comprising an effective amount of a peptide analogue of any one of claims 1-25.
27. A pharmaceutical composition of claim 26, further comprising a pharmaceutically acceptable carrier.
28. A method of eliciting an agonist effect from a GIP receptor in a subject in need thereof which comprises administering to said subject a therapeutically effective amount of a peptide analogue of any one of claims 1-25 or a pharmaceutical composition of claim 26 or claim 27.
29. A method of eliciting an antagonist effect from a GEP receptor in a subject in need thereof which comprises administering to said subject a therapeutically effective amount of a peptide analogue of any one of claims 1-25 or a pharmaceutical composition of claim 26 or claim 27.
30. A method for treating conditions or diseases mediated by GIP -receptor binding, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a peptide analogue of any one of claims 1-25 or a pharmaceutical composition of claim 26 or claim 27.
31. The method of claim 30, wherein said condition or disease mediated by GDP-receptor binding is selected from the group consisting of type 1 diabetes, type 2 diabetes, obesity, insulin resistance, glucose intolerance, fatty liver, glucagonomas, secretory disorders of the airway, metabolic disorders, arthritis, osteoporosis, central nervous system disease, restenosis, neurodegenerative disease, renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, hypertension, and disorders wherein the reduction of food intake and/or losing body weight is desired.
32. A method for treating diabetes, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a peptide analogue of any one of claims 1-25 or a pharmaceutical composition of claim 26 or claim 27.
33. The method of claim 32, wherein said diabetes is type 2 diabetes.
34. A method of treating diabetes-related disorders, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a peptide analogue of any one of claims 1-25 or a pharmaceutical composition of claim 26 or claim 27.
35. The method of claim 34, wherein said diabetes-related disorder is selected from the group consisting of hyperglycemia, hyperinsulinemia, impaired glucose tolerance, impaired fasting glucose, dyslipidemia, hypertriglyceridemia, and insulin resistance.
36. A method of treating or preventing secondary causes of diabetes, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a peptide analogue of any one of claims 1 -25 or a pharmaceutical composition of claim 26 or claim 27.
37. The method of claim 36, wherein said secondary cause is selected from the group consisting of glucocorticoid excess, growth hormone excess, pheochromocytoma, and drug-induced diabetes.
38. A method of treating obesity, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a peptide analogue of any one of claims 1-25 or a pharmaceutical composition of claim 26 or claim 27.
39. A method of stimulating insulin secretion in a subject in need thereof by administering to said subject a therapeutically effective amount of a peptide analogue of any claims 1- 25 or a pharmaceutical composition of claim 26 or claim 27.
40. Use of a peptide analogue of any one of claims 1 -25 for the manufacture of a medicament for GIP -receptor binding for the prevention or treatment of diseases or conditions related to impaired binding of GIP-receptor analogues.
41. Use according to claim 40 for the manufacture of a medicament for the prevention or treatment of pancreatic beta cell apoptosis.
42. Use according to claim 40 for the manufacture of a medicament for the potentiation of glucose dependent proliferation of pancreatic beta cells.
PCT/US2009/004552 2008-08-07 2009-08-07 Analogues of glucose-dependent insulinotropic polypeptide Ceased WO2010016940A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US13/057,760 US9074014B2 (en) 2008-08-07 2009-08-07 Analogues of glucose-dependent insulinotropic polypeptide
CN200980139514.2A CN102171244B (en) 2008-08-07 2009-08-07 Analogs of sugar-dependent insulinreleasing peptide
EA201170304A EA020019B1 (en) 2008-08-07 2009-08-07 Analogues of glucose-dependent insulinotropic polypeptide
EP20090805293 EP2328922A4 (en) 2008-08-07 2009-08-07 Analogues of glucose-dependent insulinotropic polypeptide
AU2009280017A AU2009280017B2 (en) 2008-08-07 2009-08-07 Analogues of glucose-dependent insulinotropic polypeptide
BRPI0916890A BRPI0916890A2 (en) 2008-08-07 2009-08-07 compound, pharmaceutical composition, methods for eliciting an agonist effect, and an antagonist effect of a gip receptor, for treating conditions or diseases, for treating disorders, for treating or preventing secondary causes of diabetes, and for stimulating insulin secretion in an individual , and, use of a compound
JP2011522070A JP2011530508A (en) 2008-08-07 2009-08-07 Glucose-dependent insulinotropic polypeptide analogs
MX2011001031A MX2011001031A (en) 2008-08-07 2009-08-07 Analogues of glucose-dependent insulinotropic polypeptide.
KR1020137020218A KR101417873B1 (en) 2008-08-07 2009-08-07 Analogues of glucose-dependent insulinotropic polypeptide
CA2732949A CA2732949C (en) 2008-08-07 2009-08-07 Analogues of glucose-dependent insulinotropic polypeptide
US14/717,186 US20150252092A1 (en) 2008-08-07 2015-05-20 Analogues of glucose-dependent insulinotropic polypeptide

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18819108P 2008-08-07 2008-08-07
US61/188,191 2008-08-07
US20062908P 2008-12-02 2008-12-02
US61/200,629 2008-12-02

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/057,760 A-371-Of-International US9074014B2 (en) 2008-08-07 2009-08-07 Analogues of glucose-dependent insulinotropic polypeptide
US14/717,186 Continuation US20150252092A1 (en) 2008-08-07 2015-05-20 Analogues of glucose-dependent insulinotropic polypeptide

Publications (2)

Publication Number Publication Date
WO2010016940A2 true WO2010016940A2 (en) 2010-02-11
WO2010016940A3 WO2010016940A3 (en) 2010-04-15

Family

ID=41664129

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/004552 Ceased WO2010016940A2 (en) 2008-08-07 2009-08-07 Analogues of glucose-dependent insulinotropic polypeptide

Country Status (11)

Country Link
US (2) US9074014B2 (en)
EP (2) EP2987805A3 (en)
JP (2) JP2011530508A (en)
KR (2) KR20110043686A (en)
CN (2) CN102171244B (en)
AU (1) AU2009280017B2 (en)
BR (1) BRPI0916890A2 (en)
CA (1) CA2732949C (en)
EA (1) EA020019B1 (en)
MX (1) MX2011001031A (en)
WO (1) WO2010016940A2 (en)

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011119657A1 (en) 2010-03-26 2011-09-29 Eli Lilly And Company Novel peptides and methods for their preparation and use
DE102010015123A1 (en) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
WO2012055770A1 (en) * 2010-10-25 2012-05-03 F. Hoffmann-La Roche Ag Glucose-dependent insulinotropic peptide analogs
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013164483A1 (en) * 2012-05-03 2013-11-07 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2014170496A1 (en) * 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EP2987805A2 (en) 2008-08-07 2016-02-24 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
US9486506B2 (en) 2011-09-23 2016-11-08 Novo Nordisk A/S Glucagon analogues
US9896495B2 (en) 2013-10-17 2018-02-20 Zealand Pharma A/S Acylated glucagon analogues
US9975939B2 (en) 2012-09-17 2018-05-22 Zealand Pharma A/S Glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
US10004786B2 (en) 2009-07-13 2018-06-26 Zealand Pharma A/S Acylated glucagon analogues
WO2018181864A1 (en) 2017-03-31 2018-10-04 Takeda Pharmaceutical Company Limited Gip receptor activating peptide
US10093713B2 (en) 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
US10131702B2 (en) 2013-11-06 2018-11-20 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
US10294303B2 (en) 2015-12-23 2019-05-21 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
US10336802B2 (en) 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
US10442847B2 (en) 2012-07-23 2019-10-15 Zealand Pharma A/S Glucagon analogues
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US10604555B2 (en) 2018-05-04 2020-03-31 Novo Nordisk A/S GIP derivatives and uses thereof
US10905772B2 (en) 2017-01-17 2021-02-02 Amgen Inc. Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)
US10968266B2 (en) 2014-09-05 2021-04-06 University Of Copenhagen GIP peptide analogues
WO2021110845A1 (en) * 2019-12-03 2021-06-10 Antag Therapeutics Aps Optimized gip peptide analogues
WO2021235915A1 (en) * 2020-05-22 2021-11-25 한미약품 주식회사 Liquid formulation
US11572399B2 (en) 2017-05-31 2023-02-07 University Of Copenhagen Long-acting GIP peptide analogues
US12187773B2 (en) 2018-12-03 2025-01-07 Antag Therapeutics Aps Modified GIP peptide analogues
US12435149B2 (en) 2017-06-20 2025-10-07 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
US12465652B2 (en) 2017-06-21 2025-11-11 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteins

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102170895A (en) 2008-08-07 2011-08-31 益普生制药股份有限公司 Glucose-dependent insulinotropic peptide analogs
FR2994848B1 (en) * 2012-08-30 2014-08-22 Univ Paris Curie TREATMENT OF ARTHROSIS BY INCRETINED HORMONES OR THEIR ANALOGUES
CN107188953B (en) * 2017-07-11 2020-04-28 中国农业科学院北京畜牧兽医研究所 Glucagon-like peptide-1 analogs and uses thereof
JP7503148B2 (en) * 2020-04-29 2024-06-19 ワンジーン バイオテクノロジー インコーポレイテッド Novel protein conjugate and its use for preventing or treating non-alcoholic steatohepatitis, obesity and diabetes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082928A2 (en) 2004-02-25 2005-09-09 University Of Ulster Peptide analogues of gip for treatment of diabetes, insulin resistance and obesity

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0478101B1 (en) 1990-09-24 2001-08-29 W.R. Grace & Co.-Conn. Therapeutic use of peptides having thrombospondin-like activity
JPH04145099A (en) 1990-10-05 1992-05-19 Sanwa Kagaku Kenkyusho Co Ltd Polypeptide derivative having gip-like activity and use thereof
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
HU225496B1 (en) * 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
WO1998024464A1 (en) 1996-12-03 1998-06-11 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
US7091183B1 (en) * 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
ES2217738T3 (en) 1998-01-29 2004-11-01 Poly-Med Inc. ABSORBABLE MICROPARTICLES.
WO2000004916A1 (en) 1998-07-23 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Encapsulation of water soluble peptides
AR020650A1 (en) 1998-08-10 2002-05-22 Poly Med Inc PHOSPHORILED AND CONJUGATED POLYMERS OF THE SAME
CA2349346A1 (en) 1998-11-02 2000-05-11 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Lactone bearing absorbable polymers
CZ295889B6 (en) * 1998-12-07 2005-11-16 Societe De Conseils De Recherches Et D'application GLP-1 analogues having arginine in positions 26 and 34, their use and pharmaceutical compositions in which the analogues are comprised
DE60012721D1 (en) 1999-03-29 2004-09-09 Uutech Ltd ANALOGS OF THE GASTRIC INHIBITIVE PEPTIDE AND THEIR USE FOR THE TREATMENT OF DIABETES
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
EP1392484B1 (en) * 2001-04-06 2013-06-12 California Institute Of Technology High throughput screening of crystalization of materials
TWI240632B (en) 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
US20030232761A1 (en) * 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
JP4699374B2 (en) 2003-05-15 2011-06-08 トラスティーズ オブ タフツ カレッジ Stable peptide and polypeptide analog therapeutic agents
MXPA05007210A (en) * 2003-11-13 2006-02-10 Hanmi Pharm Ind Co Ltd Protein complex using immunoglobulin fragment andmethod for the preparation thereof.
EP1711523B1 (en) * 2003-12-16 2012-10-10 Ipsen Pharma Analogues of glp-1
CN1938334A (en) * 2004-01-30 2007-03-28 瓦拉塔药品公司 Combined use of a GLP-1 agonist and gastrin compounds
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
JP2008530130A (en) 2005-02-11 2008-08-07 アミリン・ファーマシューティカルズ，インコーポレイテッド GIP analogs and hybrid polypeptides with selectable properties
WO2006121904A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
CA2623412A1 (en) * 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
WO2007028633A2 (en) * 2005-09-08 2007-03-15 Uutech Limited Treatment of diabetes related obesity
JPWO2007049695A1 (en) 2005-10-26 2009-04-30 中外製薬株式会社 Aggregating GLP-1 analog and sustained release pharmaceutical composition
CA2660835A1 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable propperties
CN102170895A (en) 2008-08-07 2011-08-31 益普生制药股份有限公司 Glucose-dependent insulinotropic peptide analogs
JP2011530509A (en) 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ Glucose-dependent insulinotropic polypeptide (GIP) analog modified at the N-terminus
US9074014B2 (en) 2008-08-07 2015-07-07 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
PT2320923E (en) 2008-08-07 2015-02-24 Ipsen Pharma Sas Truncated analogues of glucose-dependent insulinotropic polypeptide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082928A2 (en) 2004-02-25 2005-09-09 University Of Ulster Peptide analogues of gip for treatment of diabetes, insulin resistance and obesity

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CREUTZFELDT, W. ET AL., DIABETOLOGIA, vol. 16, 1979, pages 75 - 85
CREUTZFELDT, W. ET AL., DIABETOLOGIA, vol. 28, 1985, pages 565 - 573
FEHMANN, H. C. ET AL., FEBS LETT., vol. 252, 1989, pages 109 - 112
GAULT, V. A. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 308, 2003, pages 207 - 213
GREEN, B. D. ET AL., CURRENT PHARMACEUTICAL DESIGN, vol. 10, 2004, pages 3651 - 3662
NAUCK ET AL., J. CLIN. ENDORINOL. METAB., vol. 69, 1989, pages 654 - 662
See also references of EP2328922A4
TRUMPER ET AL., DIABETES, vol. 52, 2003, pages 741 - 750
VISBOLL, T., DAN. MED. BULL., vol. 51, 2004, pages 364 - 70
WANG ET AL., MOL. CELL. ENDOCRINOL., vol. 116, 1996, pages 81 - 87

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2987805A2 (en) 2008-08-07 2016-02-24 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
US10004786B2 (en) 2009-07-13 2018-06-26 Zealand Pharma A/S Acylated glucagon analogues
US8815811B2 (en) 2010-03-26 2014-08-26 Eli Lilly And Company Peptides and methods for their preparation and use
JP2013523647A (en) * 2010-03-26 2013-06-17 イーライ リリー アンド カンパニー Novel peptides and methods for their preparation and use
EA022489B1 (en) * 2010-03-26 2016-01-29 Эли Лилли Энд Компани NEW PEPTIDES AND METHODS FOR THEIR RECEPTION AND APPLICATION
CN102821779B (en) * 2010-03-26 2015-03-11 伊莱利利公司 Novel peptide and its preparation method and application
AU2011232597B2 (en) * 2010-03-26 2015-01-29 Eli Lilly And Company Novel peptides and methods for their preparation and use
CN102821779A (en) * 2010-03-26 2012-12-12 伊莱利利公司 Novel peptides and methods for their preparation and use
KR101407775B1 (en) 2010-03-26 2014-06-17 일라이 릴리 앤드 캄파니 Novel peptides and methods for their preparation and use
WO2011119657A1 (en) 2010-03-26 2011-09-29 Eli Lilly And Company Novel peptides and methods for their preparation and use
DE102010015123A1 (en) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012055770A1 (en) * 2010-10-25 2012-05-03 F. Hoffmann-La Roche Ag Glucose-dependent insulinotropic peptide analogs
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9486506B2 (en) 2011-09-23 2016-11-08 Novo Nordisk A/S Glucagon analogues
US9486505B2 (en) 2011-09-23 2016-11-08 Novo Nordisk A/S Glucagon analogues
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2013255751B2 (en) * 2012-05-03 2017-10-05 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
EA028665B1 (en) * 2012-05-03 2017-12-29 Зилэнд Фарма А/С Gip-glp-1 dual agonist compounds and methods
WO2013164483A1 (en) * 2012-05-03 2013-11-07 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
US10100097B2 (en) 2012-05-03 2018-10-16 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
US10442847B2 (en) 2012-07-23 2019-10-15 Zealand Pharma A/S Glucagon analogues
US11795204B2 (en) 2012-07-23 2023-10-24 Zealand Pharma A/S Glucagon analogues
US10253081B2 (en) 2012-09-17 2019-04-09 Zealand Pharma A/S Glucagon analogues
US9975939B2 (en) 2012-09-17 2018-05-22 Zealand Pharma A/S Glucagon analogues
RU2683039C2 (en) * 2013-04-18 2019-03-26 Ново Нордиск А/С Stable protracted glp-1/glucagon receptor co-antagonists for medical use
AU2014255608B2 (en) * 2013-04-18 2018-01-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
WO2014170496A1 (en) * 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US9474790B2 (en) 2013-04-18 2016-10-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
US9751927B2 (en) 2013-04-18 2017-09-05 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
US11034747B2 (en) 2013-10-17 2021-06-15 Zealand Pharma A/S Glucagon analogues and methods of use
US12473339B2 (en) 2013-10-17 2025-11-18 Zealand Pharma A/S Acylated glucagon analogues
US9896495B2 (en) 2013-10-17 2018-02-20 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
US11884713B2 (en) 2013-10-17 2024-01-30 Zealand Pharma A/S Acylated glucagon analogues
US11091528B2 (en) 2013-10-17 2021-08-17 Zealand Pharma A/S Acylated glucagon analogues
US10457714B2 (en) 2013-10-17 2019-10-29 Zealand Pharma A/S Acylated glucagon analogues
US10093713B2 (en) 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
US11111285B2 (en) 2013-11-06 2021-09-07 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
US11008375B2 (en) 2013-11-06 2021-05-18 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
US10131702B2 (en) 2013-11-06 2018-11-20 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US10968266B2 (en) 2014-09-05 2021-04-06 University Of Copenhagen GIP peptide analogues
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
US11814417B2 (en) 2014-10-29 2023-11-14 Zealand Pharma A/S GIP agonist compounds and methods
US11001619B2 (en) 2014-10-29 2021-05-11 Zealand Pharma A/S GIP agonist compounds and methods
US11274136B2 (en) 2015-04-16 2022-03-15 Zealand Pharma A/S Acylated glucagon analogue
US10336802B2 (en) 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
US11046774B2 (en) 2015-12-23 2021-06-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
US10294303B2 (en) 2015-12-23 2019-05-21 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
US12252540B2 (en) 2015-12-23 2025-03-18 Amgen Inc. Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR)
US10905772B2 (en) 2017-01-17 2021-02-02 Amgen Inc. Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)
US12214051B2 (en) 2017-01-17 2025-02-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)
US11174301B2 (en) 2017-03-31 2021-11-16 Takeda Pharmaceutical Company Limited Peptide compound
WO2018181864A1 (en) 2017-03-31 2018-10-04 Takeda Pharmaceutical Company Limited Gip receptor activating peptide
US10435445B2 (en) 2017-03-31 2019-10-08 Takeda Pharmaceutical Company Limited Peptide compound
US11572399B2 (en) 2017-05-31 2023-02-07 University Of Copenhagen Long-acting GIP peptide analogues
US12435149B2 (en) 2017-06-20 2025-10-07 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
US12465652B2 (en) 2017-06-21 2025-11-11 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteins
US10604555B2 (en) 2018-05-04 2020-03-31 Novo Nordisk A/S GIP derivatives and uses thereof
US11633459B2 (en) 2018-05-04 2023-04-25 Novo Nordisk A/S GIP derivatives and uses thereof
US12187773B2 (en) 2018-12-03 2025-01-07 Antag Therapeutics Aps Modified GIP peptide analogues
US12297250B2 (en) 2018-12-03 2025-05-13 Antag Therapeutics Aps Modified GIP peptide analogues
US20230416330A1 (en) * 2019-12-03 2023-12-28 Antag Therapeutics Aps Optimized GIP Peptide Analogues
CN114761420A (en) * 2019-12-03 2022-07-15 安泰博医药 Optimized GIP peptide analogs
WO2021110845A1 (en) * 2019-12-03 2021-06-10 Antag Therapeutics Aps Optimized gip peptide analogues
WO2021235915A1 (en) * 2020-05-22 2021-11-25 한미약품 주식회사 Liquid formulation

Also Published As

Publication number Publication date
JP2011530508A (en) 2011-12-22
CA2732949A1 (en) 2010-02-11
JP2014028846A (en) 2014-02-13
US20150252092A1 (en) 2015-09-10
EP2987805A2 (en) 2016-02-24
CN102171244B (en) 2015-05-13
MX2011001031A (en) 2011-04-26
AU2009280017B2 (en) 2013-01-10
BRPI0916890A2 (en) 2019-09-24
US20110136733A1 (en) 2011-06-09
EP2328922A2 (en) 2011-06-08
KR20130093692A (en) 2013-08-22
EP2987805A3 (en) 2016-04-13
CA2732949C (en) 2016-12-20
US9074014B2 (en) 2015-07-07
WO2010016940A3 (en) 2010-04-15
KR101417873B1 (en) 2014-07-09
CN104829706A (en) 2015-08-12
CN102171244A (en) 2011-08-31
KR20110043686A (en) 2011-04-27
EP2328922A4 (en) 2013-01-02
AU2009280017A1 (en) 2010-02-11
JP5865324B2 (en) 2016-02-17
EA201170304A1 (en) 2011-10-31
EA020019B1 (en) 2014-08-29

Similar Documents

Publication Publication Date Title
US9074014B2 (en) Analogues of glucose-dependent insulinotropic polypeptide
US9072703B2 (en) Glucose-dependent insulinotropic polypeptide analogues
EP2320923B1 (en) Truncated analogues of glucose-dependent insulinotropic polypeptide
US8999940B2 (en) Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal
HK1154790B (en) Glucose-dependent insulinotropic polypeptide analogues
HK1154787B (en) Truncated analogues of glucose-dependent insulinotropic polypeptide

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980139514.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09805293

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009280017

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/001031

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 491/KOLNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2732949

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 13057760

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2011522070

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009280017

Country of ref document: AU

Date of ref document: 20090807

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20117003753

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201170304

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2009805293

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0916890

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110207